CA2533701A1 - Oligomeric compounds and compositions for use in modulation of small non-coding rnas - Google Patents

Oligomeric compounds and compositions for use in modulation of small non-coding rnas Download PDF

Info

Publication number
CA2533701A1
CA2533701A1 CA002533701A CA2533701A CA2533701A1 CA 2533701 A1 CA2533701 A1 CA 2533701A1 CA 002533701 A CA002533701 A CA 002533701A CA 2533701 A CA2533701 A CA 2533701A CA 2533701 A1 CA2533701 A1 CA 2533701A1
Authority
CA
Canada
Prior art keywords
mir
mirna
oligomeric compound
cell
precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002533701A
Other languages
French (fr)
Inventor
Christine Esau
Bridget Lollo
C. Frank Bennett
Susan M. Freier
Richard H. Griffey
Brenda F. Baker
Timothy Vickers
Eric G. Marcusson
Erich Koller
Eric E. Swayze
Ravi Jain
Balkrishen Bhat
Eigen Peralta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regulus Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34139820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2533701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2533701A1 publication Critical patent/CA2533701A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Abstract

Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.

Claims (110)

What is claimed is:
1. An oligomeric compound comprising a first region and a second region, wherein:

at least one region contains a modification; and a portion of the oligomeric compound is targeted to a small non-coding RNA
target nucleic acid, wherein the small non-coding RNA target nucleic acid is a miRNA, or any precursor thereof.
2. An oligomeric compound of claim 1 wherein the oligomeric compound is targeted to a miRNA.
3. An oligomeric compound of claim 2 wherein the miRNA is mir-10a, mir-15a-1, mir-15a-2, mir-15b, mir-16-1, mir-16-2, mir-16-3, mir-19b-2, mir-21, mir-22, mir-23a, mir-23b, mir-24-2, mir-26a, mir-27b, mir-29a-1, mir-29b-1, mir-29b-2, mir-29c, mir-30a, mir-30b, mir-30d, mir-92-1, mir-92-2, mir-93, mir-94/mir-106b, mir-96, mir-100-1, mir-103-l, mir-106, mir-107, mir-123/mir-126, mir-123/mir-126as, mir-125b-1, mir-128b, mir-129-1, mir-130b, mir-131-1/mir-9, mir-131-2/mir-9, mir-131-3/mir-9, mir-133b, mir-138, mir-140, mir-141, mir-143, mir-144, mir-145, mir-152, mir-161, mir-173, mir-181a-1, mir-182, mir-183, mir-184, mir-187, mir-191, mir-192-1, mir-196-1, mir-196-2, mir-203, mir-205, mir-206, mir-213/mir-181a, mir-210, mir-211, mir-215, mir-216, mir-217, mir-219, mir-220, mir-221, mir-222, mir-223, mir-321-1, hypothetical miRNA-30, hypothetical miRNA-039, hypothetical miRNA-111, hypothetical mil2NA-120, hypothetical miRNA-138, hypothetical miRNA-142, hypothetical miRNA-144, hypothetical miRNA-154, hypothetical miRNA-161, hypothetical miRNA-170, hypothetical miRNA-179, hypothetical miRNA-181, mir-27 (Mourelatos), mir-93 (Mourelatos), mir-95 (Mourelatos), mir-99 (Mourelatos), or mir-244* (Kosik), or a precursor thereof.
4. The oligomeric compound of claim 1 wherein the oligomeric compound is targeted to a region flanking a Drosha cleavage site within a pri-miRNA.
5. The oligomeric compound of claim 1 wherein the oligomeric compound stimulates an increase in expression of a pri-miRNA.
6. An oligomeric compound of claim 1 further modified to comprise one or more stabilizing groups attached to one or both termini of the oligomeric compound.
7. An oligomeric compound of claim 6 wherein the stabilizing group is a cap structure.
8. A compound of claim 1 wherein the oligomeric compound is an miRNA mimic 17 to 25 nucleotides in length.
9. An oligomeric compound having a sequence essentially complementary to a target RNA, wherein the oligomeric compound comprises an isolated or purified oligomeric compound, wherein the oligomeric compound is 15 to 30 nucleotides in length, wherein the oligomeric compound comprises a sequence corresponding to a portion of the sequence of a larger oligonucleotide, and wherein the larger oligonucleotide includes a stemloop structure.
10. An oligomeric compound of claim 9 wherein the oligomeric compound includes at least one modified subunit.
11. An oligomeric compound of claim 9 wherein the oligomeric compound is 17 to subunits in length.
12. An oligomeric compound of claim 9 wherein the oligomeric compound has a sequence corresponding to a portion of one of the stems of the stemloop structure of the larger oligonucleotide.
13. An oligomeric compound of claim 12 wherein the oligomeric compound comprises a sequence corresponding to a portion of the 5' stem of the larger oligonucleotide or a portion of the 3' stem of the larger oligonucleotide.
14. An oligomeric compound comprising a sequence recited in any one of Tables herein.
15. A composition comprising a first oligomeric compound and a second oligomeric compound, wherein:

at least one of the first or second oligomeric compounds contains a modification;
at least a portion of the first oligomeric compound is capable of hybridizing with at least a portion of the second oligomeric compound; and at least a portion of the first oligomeric compound is targeted to a small non-coding RNA target nucleic acid, wherein the small non-coding RNA target nucleic acid is a miRNA, or any precursor thereof.
16. A composition of claim 15 wherein the first and said second oligomeric compounds are oligonucleotides.
17. A composition of claim 15 wherein the first and second oligomeric compounds comprise an antisense/sense pair of oligonucleotides.
18. A composition of claim 15 wherein each of the first and second oligomeric compounds comprises 17 to 25 nucleotides.
19. A composition of claim 15 wherein the first oligomeric compound comprises an antisense oligonucleotide.
20. A composition of claim 19 wherein the second oligomeric compound comprises a sense oligonucleotide.
21. A composition of claim 19 wherein the second oligomeric compound comprises an oligonucleotide having a plurality of ribose nucleotide units.
22. The composition of claim 15 wherein the miRNA is mir-30a or a precursor thereof.
23. A pharmaceutical composition comprising the composition of claim 15 and a pharmaceutically acceptable carrier.
24. A kit or assay device comprising the composition of claim 15.
25. A method of modulating the expression of a small non-coding RNA target nucleic acid in a cell, tissue, or animal comprising contacting the cell, tissue, or animal with a composition of claim 15 or with the oligomeric compound of claim 1.
26. A method of treating or preventing a disease or disorder associated with a small non-coding RNA target nucleic acid comprising contacting an animal having or predisposed to the disease or disorder with a therapeutically effective amount of a composition of claim 15 or compound of claim 1.
27. A method of claim 26 wherein the disease or disorder is a result of chromosomal nondisjunction, an altered methylation state of chromosomes, an altered acetylation state of chromosomes, or an altered pseudouridylation state of chromosomes.
28. A method of claim 26 wherein the disease or disorder is a hyperproliferative condition, diabetes, obesity, hyperlipidemia, atherosclerosis, atherogenesis, hypertension, anorexia, Alzheimers disease, a central nervous system injury, or neurodegenerative disorder.
29. The method of claim 28 wherein the hyperproliferative condition is cancer, neoplasia, or angiogenesis.
30. A method of claim 28 wherein the diabetes is Type 2 diabetes.
31. A method of claim 26 wherein the miRNA is a let-7 homolog, mir-10a, mir-19b-2, mir-23b, mir-29a-l, mir-29b, mir-30b, mir-92-1, mir-93 (Mourelatos), mir-94/mir-106b, mir-106, mir-123/mir-126, mir-123/mir-126as, mir-125b-1, mir-129-1, mir-131-1/mir-9, mir-131-2/mir-9, mir-131-3/mir-9, mir-133b, mir-138, mir-140, mir-141, mir-143, mir-144, mir-145, mir-161, mir-173, mir-181, mir-182, mir-183, mir-184, mir-187, mir-191, mir-192-1, mir-196, mir-196-2, mir-203, mir-206, mir-210, mir-217, mir-220, mir-221, mir-222, mir-223 or mir-321-1, or a precursor thereof.
32. A method of treating a condition in an animal comprising contacting an animal with an oligomeric compound comprising a first region and a second region, wherein at least one region contains a modification, and wherein a portion of the oligomeric compound can hybridize to a small non-coding RNA target nucleic acid, wherein the small non-coding RNA
target nucleic acid is a miRNA, a small temporal RNA, siRNA, small non-messenger RNA, a small nuclear RNA, a small nucleolar RNA, a tiny noncoding RNA, a rasiRNA, or any precursor thereof, and wherein adipocyte differentiation is stimulated in the animal.
33. A method of treating or preventing a disease or disorder associated with comprising contacting an animal having or predisposed to the disease or disorder with a therapeutically effective amount of single or double-stranded mimics of mir-15 or mir-16.
34. A method of screening an oligomeric compound for an effect on miRNA
signaling comprising:

contacting a cell with a vector that expresses a miRNA precursor, wherein the miRNA
precursor can produce a miRNA;

contacting the cell with the oligomeric compound;

contacting the cell with a reporter vector that comprises a target site for the miRNA that is produced by the miRNA precursor; and assaying the cell or lysate therefrom for reporter vector activity, wherein a reduction of reporter vector activity indicates that the oligomeric compound has no effect on miRNA
signaling, and wherein an increase in reporter vector activity indicates that the oligomeric compound has an effect on miRNA signaling.
35. A method of claim 34 wherein the cell is a 293T cell.
36. A method of claim 34 wherein the miRNA is mir-30a.
37. A method of claim 34 wherein the reporter vector comprises four tandem repeats of the target site for mir-30a.
38. A method of claim 34 wherein the oligomeric compound is a chimeric oligonucleotide gapmer comprising a central gap region consisting of ten 2'-deoxynucleotides, which is flanked on both sides by five-nucleotide wings.
39. A method of claim 38 wherein the wings comprise 2'-methoxyethoxy nucleotides.
40. A method of claim 39 wherein all cytidine residues are 5-methylcytidines.
41. A method of claim 34 wherein the oligomeric compound comprises 2'-methoxyethoxy nucleotides throughout with either phosphorothioate or phosphodiester internucleoside linkages.
42. A method of claim 34 wherein the oligomeric compound targets the pre-loop of the miRNA precursor or forms a pseudo half knot compound with the miRNA precursor.
43. A method of screening a miRNA precursor for an effect on miRNA signaling comprising:

contacting a cell with a miRNA precursor, wherein the miRNA precursor can produce a miRNA, and wherein the miRNA precursor is 110 to 450 nucleotides in length;

contacting the cell with a reporter vector that comprises a target site for the miRNA that is produced by the miRNA precursor;

assaying the cell or lysate therefrom for reporter vector activity; and comparing the amount of reporter activity from the cell contacted with the miRNA

precursor, or lysate therefrom, to the amount of reporter activity from a cell not contacted with the miRNA precursor, or lysate therefrom, wherein a lower amount of reporter activity from the cell contacted with the miRNA precursor, or lysate therefrom, relative to the amount of reporter activity from the cell not contacted with the the miRNA precursor, or lysate therefrom, indicates that the miRNA precursor has an effect on miRNA signaling.
44. The method of claim 43 further comprising:

contacting the cell with an oligomeric compound targeted to the miRNA or miRNA
precursor, wherein an increase in reporter vector activity indicates that the oligomeric compound affects miRNA signaling.
45. A method of claim 43 wherein the cell is a HeLa cell.
46. A method of claim 43 wherein the miRNA is mir-143, mir-21, mir-23b, or mir-15a, or a precursor thereof.
47. A method of claim 43 wherein the reporter vector comprises two or more tandem repeats of the target site for the miRNA.
48. A method of screening an oligomeric compound for an effect on miRNA
signaling comprising:

contacting a cell with an oligomeric compound that mimics a miRNA precursor, wherein the oligomeric compound that mimics the miRNA precursor can produce a miRNA;

contacting the cell with a reporter vector that comprises a target site for the miRNA
produced by the oligomeric compound that mimics the miRNA precursor;

assaying the cell or lysate therefrom for reporter vector activity; and comparing the amount of reporter activity from the cell contacted with the oligomeric compound that mimics the miRNA precursor, or lysate therefrom, to the amount of reporter activity from a cell not contacted with the oligomeric compound that mimics the miRNA
precursor, or the lysate therefrom, wherein a lower amount of reporter activity from the cell contacted with the oligomeric compound that mimics the miRNA precursor, or lysate therefrom, relative to the amount of reporter activity from the cell not contacted with the oligomeric compound that mimics the miRNA precursor, or the lysate therefrom, indicates that the oligomeric compound has an effect on miRNA signaling.
49. The method of claim 48 further comprising contacting the cell with a second oligomeric compound targeted to the oligomeric compound that mimics the miRNA precursor, wherein an increase in reporter vector activity indicates that the second oligomeric compound effects miRNA signaling.
50. The method of claim 48 wherein the cell is a HeLa cell.
51. A method of claim 48 wherein the miRNA is mir-143, mir-23b, mir-21, or mir-15a, or a precursor thereof.
52. A method of claim 48 wherein the reporter vector comprises multiple target sites for the miRNA or mimic.
53. A method of any of claims 34, 43, or 48 wherein the reporter vector comprises a target site originally found within the coding sequence of an mRNA.
54. A method of any of claims 34, 43, or 48 wherein the target site is cloned into the 3'-UTR of the reporter vector.
55. A method of any of claims 34, 43, or 48 wherein the reporter vector is a luciferase reporter vector and the reporter vector activity is luciferase expression.
56. A method of any of claims 34, 43, or 48 wherein miRNA precursor is produced in vitro using T7 RNA polymerase and a DNA template produced by polymerase chain reaction.
57. A method of claim 49 wherein the second oligomeric compound comprises a phosphorothioate or phosphodiester backbone throughout.
58. A method of claim 44 or 49 wherein the oligomeric compound or second oligomeric compound, respectively, is a chimeric oligonucleotide gapmer comprising a central gap region consisting of ten 2'-deoxynucleotides, which is flanked on both sides by five-nucleotide wings.
59. A method of claim 58 wherein the wings comprise 2'-methoxyethoxy nucleotides.
60. A method of claim 59 wherein all cytidine residues are 5-methylcytidines.
61. A method of claim 44 or 49 wherein the oligomeric compound or second oligomeric compound, respectively, comprises 2'-methoxyethoxy nucleotides throughout with either phosphorothioate or phosphodiester internucleoside linkages.
62. A method of claim 44 or 49 wherein the oligomeric compound or second oligomeric compound, respectively, targets the pre-loop of the miRNA precursor or forms a pseudo half knot compound with the miRNA precursor.
63. A method of modulating translation comprising:

contacting a system with one or more oligomeric compounds that specifically hybridize to a small non-coding RNA nucleic acid, wherein the small non-coding RNA
nucleic acid is a miRNAor any precursor thereof; and assaying the oligomeric compounds for oligomeric compounds that modulate translation of an endogenous gene regulated by the small non-coding RNA nucleic acid.
64. A method of claim 63 wherein the modulation is measured by a western blot of the protein encoded by the endogenous gene.
65. A method of modulating translation comprising:

contacting a system with one or more oligomeric compounds that mimic a small non-coding RNA nucleic acid, wherein the small non-coding RNA nucleic acid is a miRNA, or any precursor thereof; and assaying the oligomeric compounds for oligomeric compounds that modulate translation of an endogenous gene regulated by the small non-coding RNA nucleic acid.
66. A method of claim 65 wherein the modulation is measured by a western blot of the protein encoded by the endogenous gene.
67. A method of modulating apoptosis comprising contacting a system with one or more oligomeric compounds that specifically hybridize to a small non-coding RNA
nucleic acid, wherein the small non-coding RNA nucleic acid is a miRNA, or any precursor thereof.
68. A method of claim 67 wherein the modulation is measured by a caspase assay.
69. A method of modulating apoptosis comprising contacting a system with one or more oligomeric compounds that mimic a small non-coding RNA nucleic acid, wherein the small non-coding RNA nucleic acid is a miRNA, or any precursor thereof.
70. A method of claim 69 wherein the modulation is measured by a caspase assay.
71. A method of modulating conversion of a precursor miRNA into a miRNA
comprising:

assaying a library of oligomeric compounds for oligomeric compounds that bind to the precursor miRNA, wherein the precursor miRNA is from 50 to 110 nucleotides in length and has a hairpin structure, and wherein the precursor miRNA is a substrate for an RNAse III enzyme;

selecting one or more of the oligomeric compounds; and contacting the precursor miRNA with the one or more selected oligomeric compounds to modulate the interaction of the RNAse III enzyme and the precursor miRNA.
72. A method of claim 71 wherein the contacting comprises inhibiting processing of the precursor miRNA to the miRNA by the RNAse III enzyme.
73. A method of modulating cellular differentiation comprising contacting a cell or tissue with an oligomeric compound comprising a first region and a second region, wherein at least one region contains a modification, and wherein a portion of the oligomeric compound can hybridize to a small non-coding RNA target nucleic acid, wherein the small non-coding RNA target nucleic acid is a miRNA, or any precursor thereof.
74. A method of claim 73 wherein the cell or tissue is an adipocyte cell or tissue.
75. A method of claim 73 wherein the small non-coding RNA target nucleic acid is mir-145.
76. A method of identifying an RNA transcript bound to a small non-coding RNA
comprising:

isolating RNA from a cell;
producing and amplifying cDNA from the isolated RNA;
performing 5' RACE-PCR using the small non-coding RNA as a primer;
performing 3' RACE-PCR using the antisense of the small non-coding RNA as a primer; and identifying RACE-PCR products.
77. A method of claim 76 wherein the RNA transcript is an mRNA encoding the human HSPC056 protein, a transcript encoding UNR, aminolevulinate, delta-, dehydratase (ALAD), valosin-containing protein (VCP), or caveolin, and the small non-coding RNA is mir-143.
78. A method of arresting or delaying entry of a cell at the G2/M phase comprising contacting a cell with one or more oligomeric compounds that specifically hybridize to a small non-coding RNA nucleic acid, wherein the small non-coding RNA nucleic acid is a miRNA, or any precursor thereof.
79. The method of claim 78 wherein the oligomeric compound targets mir-143, mir-203, mir-103-1, mir-106, mir-145, mir-205, mir-131/mir-9, mir-213/mir-181a-2, mir-26a-1, mir-192, mir-182, mir-100-1, mir-30d, mir-106, mir-216, mir-23a, mir-96, mir-130b, mir-(Mourelatos), or a precursor thereof.
80. A method of interfering with chromosome segregation comprising contacting a cell with one or more oligomeric compounds that specifically hybridize to a small non-coding RNA
nucleic acid, wherein the small non-coding RNA nucleic acid is a miRNA, or any precursor thereof.
81. The method of claim 80 wherein the oligomeric compound targets mir-26a, mir-144, mir-205, mir-216, mir-181 a, or mir-92-2, or a precursor thereof.
82. A method of triggering apoptosis comprising contacting a cell with one or more oligomeric compounds that specifically hybridize to a small non-coding RNA
nucleic acid, wherein the small non-coding RNA nucleic acid is a miRNA, or any precursor thereof.
83. The method of claim 82 wherein the oligomeric compound targets mir-203, mir-103-1, mir-26a, mir-93, mir-192, mir-106, or mir-205, or a precursor thereof.
84. A method of detecting a miRNA precursor comprising:
contacting a cell or a tissue with an oligomeric compound targeting human Dicer; and determining the amount of miRNA precursor.
85. The method of claim 84 wherein the amount of miRNA precursor is determined by Northern blot, real-time RT-PCR or RPA.
86. The method of claim 85 wherein the amount is determined qualitatively or quantitatively.
87. A method of identifying a miRNA target comprising:
contacting a cell or a tissue with an oligomeric compound targeting human Dicer to modulate the amount of mature miRNAs in the cell or tissue;
isolating total RNA or protein from the cell or tissue;
comparing the amount of at least one target RNA or protein from a cell or tissue not contacted with the oligomeric compound to the amount of the same target RNA or protein in a cell or tissue contacted with the oligomeric compound; and identifying at least one target RNA or protein for which there is a change in amount.
88. The method of claim 87 wherein the amount of mature miRNAs is decreased.
89. A method of modulating cellular differentiation comprising contacting a cell or tissue with an oligomeric compound targeting human Dicer to modulate the amount of miRNA
precursors in the cell or tissue.
90. The method of claim 89 wherein the cell or tissue is an adipocyte cell or tissue.
91. A method of modulating apoptosis comprising contacting a cell or a tissue with an oligomeric compound targeting human Dicer to modulate the amount of miRNA
precursors in the cell or tissue.
92. The method of claim 91 wherein apoptosis is measured by the caspase assay.
93. The method of claim 91 wherein the caspase assay indicates an increase in caspase activity.
94. A method of treating a condition associated with adipocyte differentiation in an animal comprising contacting the animal with an oligomeric compound comprising a first region and a second region, wherein at least one region contains a modification, and wherein a portion of the oligomeric compound can hybridize to human Dicer mRNA.
95. A method of treating or preventing a disease or disorder associated with aberrant regulation of the cell cycle by miRNAs comprising contacting the animal having or predisposed to having the disease or disorder with a therapeutically effective amount of an oligomeric compound targeting human Dicer.
96. The method of claim 95 further comprising identifying the animal having or predisposed to having the disease or disorder prior to treatment or prevention.
97. A method of claim 95 wherein the disease or disorder is a hyperproliferative condition, diabetes, obesity, hyperlipidemia, atherosclerosis, atherogenesis, or hypertension.
98. The method of claim 97 wherein the hyperproliferative condition is cancer, neoplasia, or angiogenesis.
99. The method of claim 97 wherein the diabetes is Type 2 diabetes.
100. A method of maintaining a pluripotent stem cell comprising contacting the cell with an effective amount of an oligomeric compound targeting human Dicer.
101. The method of claim 100 wherein the pluripotent stem cell is present in a sample of cord blood, bone marrow, or a cell line.
102. The method of claim 101 wherein the pluripotent stem cell is an embryonic stem cell.
103. A method of identifying a small non-coding RNA binding site comprising:
computationally deriving 30-nucleotide windows in a target nucleic acid, starting with the first nucleotide of the sequence and defining the first nucleotide in each window by shifting 1 nucleotide in the 3' direction;
assessing the bimolecular hybridization free energy of each interaction of a miRNA
with the sequence in each window of the target nucleic acid and disallowing unimolecular interactions;
plotting the resulting bimolecular hybridization free energy value against the start position of each window; and identifying those interactions with the most negative bimolecular hybridization free energy values.
104. The method of claim 103 wherein the binding site is identified in the coding sequence, 5'-UTR, or 3'-UTR of an mRNA transcript.
105. The method of claim 103 wherein the target nucleic acid is an mRNA
encoding the human ERRS protein (GenBank Accession NM_139032.1), and the miRNA is mir-143.
106. A composition comprising a first oligomeric compound and a second oligomeric compound forming a structure wherein:
the second oligomeric compound comprises a 3' dangling region comprising seven nucleotides, a second side of a first stem comprising seven nucleotides, a second side of a first internal loop comprising two nucleotides, a second side of a second stem comprising three nucleotides, a second side of a second internal loop comprising one nucleotide, a second side of a third stem comprising three nucleotides, a second side of a third internal loop comprising one nucleotide, a second side of a forth stem comprising five nucleotides, and a 5' dangling region comprising one nucleotide; and the first oligomeric compound comprises a first side of the first stem comprising seven nucleotides, a first side of the first internal loop comprising one nucleotide, a first side of the second stem comprising three nucleotides, a first side of the second internal loop comprising one nucleotide, a first side of the third stem comprising three nucleotides, a first side of the third internal loop comprising two nucleotides, and a first side of the forth stem comprising five nucleotides.
107. A composition comprising a first oligomeric compound and a second oligomeric compound forming a structure wherein:
the second oligomeric compound comprises a 3' dangling region comprising seven nucleotides, a second side of a first stem comprising three nucleotides, a second side of a first internal loop comprising one nucleotide, a second side of a second stem comprising ten nucleotides and a single nucleotide bulge, a second side of a second internal loop comprising four nucleotides, and a second side of a third stem comprising four nucleotides; and the first oligomeric compound comprises a first side of the first stem comprising three nucleotides, a first side of the first internal loop comprising one nucleotide, a first side of the second stem comprising ten nucleotides and a single nucleotide bulge, a first side of the second internal loop comprising two nucleotides, and a first side of the third stem comprising four nucleotides, and a 3' dangling region comprising one nucleotide.
10~. The composition of claim 107 wherein the single nucleotide bulge in the second oligomeric compound is present after the seventh nucleotide in the second side of the second stem numbered 5' to 3' and the single nucleotide bulge in the first oligomeric compound is present after the sixth nucleotide in the first side of the second stem numbered 5' to 3'.
109. A composition comprising a first oligomeric compound and a second oligomeric compound forming a structure wherein:
the second oligomeric compound comprises a 3' dangling region comprising eight nucleotides, a second side of a first stem comprising three nucleotides, a second side of a first internal loop comprising two nucleotides, a second side of a second stem comprising twelve nucleotides, and a 5' dangling region comprising five nucleotides; and the first oligomeric compound comprises a first 5' dangling region comprising one nucleotide, a first side of the first stem comprising three nucleotides, a first side of the first internal loop comprising four nucleotides, a first side of the second stem comprising twelve nucleotides, and a 3' dangling region comprising two nucleotides.
110. A method of claim 32 wherein the miRNA is mir-27b, mir-27 (Mourelatos), mir-99 (Mourelatos), mir-244* (Kosik), hypothetical miRNA-161, or hypothetical miRNA-170, or a precursor thereof.
CA002533701A 2003-07-31 2004-07-30 Oligomeric compounds and compositions for use in modulation of small non-coding rnas Abandoned CA2533701A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US49205603P 2003-07-31 2003-07-31
US60/492,056 2003-07-31
US51630303P 2003-10-31 2003-10-31
US60/516,303 2003-10-31
US53159603P 2003-12-19 2003-12-19
US60/531,596 2003-12-19
US56241704P 2004-04-14 2004-04-14
US60/562,417 2004-04-14
PCT/US2004/025300 WO2005013901A2 (en) 2003-07-31 2004-07-30 Oligomeric compounds and compositions for use in modulation of small non-coding rnas

Publications (1)

Publication Number Publication Date
CA2533701A1 true CA2533701A1 (en) 2005-02-17

Family

ID=34139820

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002533701A Abandoned CA2533701A1 (en) 2003-07-31 2004-07-30 Oligomeric compounds and compositions for use in modulation of small non-coding rnas

Country Status (5)

Country Link
US (27) US7683036B2 (en)
EP (2) EP2530157B1 (en)
CA (1) CA2533701A1 (en)
IL (2) IL173364A (en)
WO (1) WO2005013901A2 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338102B2 (en) 2006-07-13 2012-12-25 The Ohio State University Research Foundation Method of diagnosing poor survival prognosis colon cancer using miR-181b
US8349561B2 (en) 2007-06-15 2013-01-08 The Ohio State University Research Foundation Method for diagnosing acute lymphomic leukemia (ALL) using miR-125b
US8354229B2 (en) 2007-01-31 2013-01-15 The Ohio State University Research Foundation MiR-25-based methods for the diagnosis and prognosis of acute myeloid leukemia (AML)
US8361710B2 (en) 2006-01-05 2013-01-29 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-21
US8367632B2 (en) 2007-07-31 2013-02-05 Ohio State University Research Foundation Methods for reverting methylation by targeting methyltransferases
US8389210B2 (en) 2006-01-05 2013-03-05 The Ohio State University Research Foundation MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
US8466119B2 (en) 2007-08-22 2013-06-18 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of EPHA7 and ERK phosphorylation in human acute leukemias
US8481505B2 (en) 2005-09-12 2013-07-09 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
US8486913B2 (en) 2006-03-20 2013-07-16 The Ohio State University MicroRNA fingerprints during human megakaryocytopoiesis
US8507202B2 (en) 2006-01-05 2013-08-13 The Ohio State University Methods for diagnosing pancreatic cancer using MicroRNAs
US8598143B2 (en) 2003-11-26 2013-12-03 University Of Massachusetts Sequence-specific inhibition of small RNA function
US8658370B2 (en) 2005-08-01 2014-02-25 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
US8664192B2 (en) 2011-03-07 2014-03-04 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
US8911998B2 (en) 2007-10-26 2014-12-16 The Ohio State University Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof
US8916533B2 (en) 2009-11-23 2014-12-23 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
US8946187B2 (en) 2010-11-12 2015-02-03 The Ohio State University Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer
US9085804B2 (en) 2007-08-03 2015-07-21 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
US9125923B2 (en) 2008-06-11 2015-09-08 The Ohio State University Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
US9249468B2 (en) 2011-10-14 2016-02-02 The Ohio State University Methods and materials related to ovarian cancer
US9481885B2 (en) 2011-12-13 2016-11-01 Ohio State Innovation Foundation Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
US10758619B2 (en) 2010-11-15 2020-09-01 The Ohio State University Controlled release mucoadhesive systems

Families Citing this family (501)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US9827263B2 (en) 2002-11-05 2017-11-28 Ionis Pharmaceuticals, Inc. 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
AU2011236049A1 (en) * 2003-11-26 2011-11-03 University Of Massachusetts Sequence-specific inhibition of small RNA function
WO2005078139A2 (en) 2004-02-09 2005-08-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
AU2011239266B2 (en) * 2004-02-13 2012-11-01 Rockefeller University Anti-microRNA oligonucleotide molecules
WO2005079397A2 (en) * 2004-02-13 2005-09-01 Rockefeller University Anti-microrna oligonucleotide molecules
US8088902B2 (en) 2004-04-05 2012-01-03 The Rockefeller University DNA virus microRNA and methods for inhibiting same
US7365058B2 (en) 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
EP1747023B2 (en) 2004-05-04 2016-03-09 The Board of Trustees of The Leland Stanford Junior University Methods and compositions for reducing hcv viral genome amounts in a target cell
CA2566519C (en) 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
EP2471921A1 (en) * 2004-05-28 2012-07-04 Asuragen, Inc. Methods and compositions involving microRNA
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
CA2569419A1 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
AU2005272816B2 (en) 2004-08-10 2011-08-11 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides
WO2007148235A2 (en) * 2006-05-04 2007-12-27 Rosetta Genomics Ltd Cancer-related nucleic acids
FR2877350B1 (en) * 2004-11-03 2010-08-27 Centre Nat Rech Scient IDENTIFICATION AND USE OF miRNAs INVOLVED IN THE DIFFERENTIATION OF CELLS FROM MYELOID LEUKEMIA
EP2302054B1 (en) * 2004-11-12 2014-07-16 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
AU2014202177B2 (en) * 2004-11-12 2016-08-04 Asuragen, Inc Methods and compositions involving mirna and mirna inhibitor molecules
AU2005323166B2 (en) 2004-12-21 2011-11-10 Monsanto Technology, Llc Recombinant DNA constructs and methods for controlling gene expression
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
US20070065840A1 (en) * 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
EP1877557A2 (en) 2005-04-04 2008-01-16 The Board of Regents of The University of Texas System Micro-rna's that regulate muscle cells
GB2425311A (en) * 2005-04-15 2006-10-25 Ist Superiore Sanita Micro RNA against kit protein
EP2631293A3 (en) 2005-04-29 2013-11-20 The Rockefeller University Human microRNAs and methods for inhibiting same
CA2607256A1 (en) * 2005-05-02 2006-11-09 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
PL2002003T3 (en) * 2005-05-27 2016-06-30 Ospedale San Raffaele Srl Gene vector comprising mi-rna
WO2007030227A2 (en) 2005-07-29 2007-03-15 The Board Of Governors For Higher Education, Modified oligonucleotides containing diphosphodiester internucleotide linkages
US20070213292A1 (en) * 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
AU2006279906B2 (en) * 2005-08-10 2012-05-10 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
AU2013200489B2 (en) * 2005-08-29 2015-09-17 Regulus Therapeutics Inc. Methods for use in modulating miR-122a
WO2007027775A2 (en) * 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Methods for use in modulating mir-122a
US20090203893A1 (en) * 2005-08-29 2009-08-13 Regulus Therapeutics, Llc Antisense compounds having enhanced anti-microrna activity
AU2011254085B2 (en) * 2005-08-29 2012-11-01 Regulus Therapeutics Inc. Methods for use in modulating miR-122a
JP2007082436A (en) * 2005-09-20 2007-04-05 Bioinformatics Institute For Global Good Inc METHOD FOR PREDICTING OR IDENTIFYING TARGET mRNA CONTROLLED BY FUNCTIONAL RNA, AND APPLICATION THEREOF
JP5713377B2 (en) * 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート Natural antisense and non-coding RNA transcripts as drug targets
EP2388328A1 (en) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
AU2007223980B2 (en) 2006-03-07 2014-01-09 The Trustees Of The University Of Pennsylvania Random RNAi libraries, methods of generating same, and screening methods utilizing same
WO2007109350A2 (en) * 2006-03-23 2007-09-27 California Institute Of Technology Modulation of innate immunity receptors' signaling by micrornas mir-146a and mir-146b
US7955848B2 (en) 2006-04-03 2011-06-07 Trustees Of Dartmouth College MicroRNA biomarkers for human breast and lung cancer
US8207325B2 (en) 2006-04-03 2012-06-26 Univ. of Copenhagen MicroRNA biomarkers for human breast and lung cancer
EP2194129A3 (en) * 2006-04-03 2012-12-26 Santaris Pharma A/S Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
AU2012216487B2 (en) * 2006-04-03 2015-05-14 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
SG170773A1 (en) 2006-04-03 2011-05-30 Santaris Pharma As Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
US8586554B2 (en) 2006-05-05 2013-11-19 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of PTP1B
US20090023221A1 (en) * 2006-05-19 2009-01-22 Exigon A/S Oligonucleotide probes useful for detection and analysis of microrna precursors
AU2007266320A1 (en) * 2006-05-26 2007-12-06 Medvet Science Pty. Ltd. Methods of modulating epithelial-mesenchymal transition and mesenchymal-epithelial transition in cells and agents useful for the same
BRPI0714794A2 (en) * 2006-08-01 2013-05-21 Univ Texas identification of a micro-rna that activates beta-myosin heavy chain expression
US8476244B2 (en) 2006-08-04 2013-07-02 Dublin City University Method of producing recombinant biological products
GB2440782A (en) * 2006-08-04 2008-02-13 Cesare Peschle Uses and compositions comprising miRNAs
US20080199961A1 (en) * 2006-08-25 2008-08-21 Avi Biopharma, Inc. ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS
WO2008025073A1 (en) * 2006-08-28 2008-03-06 The University Of Western Australia Method of modulation of expression of epidermal growth factor receptor (egfr) involving mirna
AU2007299804A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. MiR-200 regulated genes and pathways as targets for therapeutic intervention
JP2010504349A (en) * 2006-09-19 2010-02-12 アシュラジェン インコーポレイテッド Genes and pathways regulated by miR-143 as targets for therapeutic intervention
CA2663962A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
MX2009003729A (en) * 2006-10-09 2009-04-22 Santaris Pharma As Rna antagonist compounds for the modulation of pcsk9.
WO2008043521A2 (en) * 2006-10-09 2008-04-17 Julius-Maximilians-Universität Würzburg Microrna (mirna) for the diagnosis and treatment of heart diseases
EP2086590A4 (en) * 2006-10-24 2011-04-06 Univ Leland Stanford Junior Modulation of t cell signaling threshold and t cell sensitivity to antigens
WO2009024834A2 (en) * 2006-12-05 2009-02-26 Rosetta Genomics Ltd Nucleic acids involved in viral infection
WO2008073919A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
EP2104735A2 (en) * 2006-12-08 2009-09-30 Asuragen, INC. Mir-21 regulated genes and pathways as targets for therapeutic intervention
EP2104737B1 (en) * 2006-12-08 2013-04-10 Asuragen, INC. Functions and targets of let-7 micro rnas
CA2671270A1 (en) * 2006-12-29 2008-07-17 Asuragen, Inc. Mir-16 regulated genes and pathways as targets for therapeutic intervention
EP2124967A4 (en) * 2007-01-26 2011-01-05 Rosetta Genomics Ltd Compositions and methods for treating hematopoietic malignancies
US20100093836A1 (en) * 2007-01-29 2010-04-15 Isis Pharmaceuticals, Inc Compounds and methods for modulating protein expression
US7601399B2 (en) * 2007-01-31 2009-10-13 Surface Modification Systems, Inc. High density low pressure plasma sprayed focal tracks for X-ray anodes
WO2008103135A2 (en) * 2007-02-16 2008-08-28 The Johns Hopkins University The micrornaome
US9006206B2 (en) 2007-02-27 2015-04-14 Rosetta Genomics Ltd. Composition and methods for modulating cell proliferation and cell death
CA2699418A1 (en) * 2007-02-27 2008-09-04 Moshe Oren Composition and methods for modulating cell proliferation and cell death
DK2149605T3 (en) 2007-03-22 2013-09-30 Santaris Pharma As Short RNA antagonist compounds to modulate the desired mRNA
JP2010521193A (en) 2007-03-22 2010-06-24 サンタリス ファーマ アー／エス RNA antagonist compounds for inhibition of APO-B100 expression
US20090105174A1 (en) * 2007-04-20 2009-04-23 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US8415096B2 (en) 2007-05-23 2013-04-09 University Of South Florida Micro-RNAs modulating immunity and inflammation
EP2559773B1 (en) * 2007-06-08 2015-04-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Methods for determining a hepatocellular carcinoma subtype
US20110046206A1 (en) * 2007-06-22 2011-02-24 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
WO2009012263A2 (en) * 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
WO2009015071A1 (en) * 2007-07-23 2009-01-29 Dharmacon, Inc. Screening of micro-rna cluster inhibitor pools
WO2009015398A1 (en) * 2007-07-26 2009-01-29 Oklahoma Medical Research Foundation Methods for inflammatory disease management
CA2694928A1 (en) * 2007-07-31 2009-02-05 Board Of Regents, The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
AU2016266042B2 (en) * 2007-07-31 2018-10-04 Board Of Regents, The University Of Texas System A micro-rna family that modulates fibrosis and uses thereof
NZ583024A (en) 2007-07-31 2012-04-27 Regents The Univeristy Of Texas System Board Of An agonist of miR-29a, miR-29b or miR-29c that prevents tissue fibrosis and uses thereof
WO2009027527A2 (en) * 2007-08-30 2009-03-05 Santaris Pharma A/S Rna antagonist compounds for the modulation of fabp4/ap2
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20090136957A1 (en) * 2007-09-15 2009-05-28 Irena Ivanovska Methods and compositions for regulating cell cycle progression via the miR-106B family
EP2205741A2 (en) 2007-10-02 2010-07-14 Amgen Inc. Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
DK2205737T3 (en) 2007-10-04 2013-05-21 Santaris Pharma As Micromirers
WO2009046426A2 (en) * 2007-10-04 2009-04-09 Isis Pharmaceuticals, Inc. Compounds and methods for improving cellular uptake of oligomeric compounds
JP5535076B2 (en) * 2007-10-29 2014-07-02 レグルス・セラピューティクス・インコーポレイテッド Targeted microRNA for treating liver cancer
DE102007052114B4 (en) 2007-10-30 2011-01-05 T2Cure Gmbh Method for modulating the function, growth or differentiation of a cell
CA2705325C (en) 2007-11-09 2016-11-01 The Board Of Regents Of The University Of Texas System Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
EP2219680A2 (en) 2007-11-13 2010-08-25 Isis Pharmaceuticals, Inc. Compounds and methods for modulating protein expression
US20100240058A1 (en) * 2007-11-23 2010-09-23 Panagene Inc. MicroRNA Antisense PNAs, Compositions Comprising the Same, and Methods for Using and Evaluating the Same
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US9090894B2 (en) * 2007-12-17 2015-07-28 California Institute Of Technology Modulating immune system development and function through microRNA MIR-146
WO2009086156A2 (en) * 2007-12-21 2009-07-09 Asuragen, Inc. Mir-10 regulated genes and pathways as targets for therapeutic intervention
US20090202493A1 (en) * 2008-01-30 2009-08-13 The General Hospital Corporation Mir-150 for the treatment of blood disorders
WO2009100430A2 (en) * 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
US20130023498A1 (en) * 2008-02-20 2013-01-24 The Wistar Institute and North Carolina State University MicroRNA Modulators and Method for Identifying and Using the Same
US8338392B2 (en) * 2008-02-20 2012-12-25 The Wistar Institute MicroRNA modulators and method for identifying and using the same
CA2717026A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
WO2009111643A2 (en) * 2008-03-06 2009-09-11 Asuragen, Inc. Microrna markers for recurrence of colorectal cancer
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
US8202848B2 (en) 2008-03-17 2012-06-19 Board Of Regents, The University Of Texas System Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration
AU2009228393B2 (en) 2008-03-24 2014-10-02 New York University Compositions and methods for diagnosing and treating melanoma
US20100113284A1 (en) * 2008-04-04 2010-05-06 Alexander Aristarkhov Small interfering rna (sirna) target site blocking oligos and uses thereof
WO2009126650A2 (en) * 2008-04-07 2009-10-15 Cornell Research Foundation, Inc. Inhibition of angiognesis
WO2009126726A1 (en) * 2008-04-08 2009-10-15 Asuragen, Inc Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
AU2009234266B2 (en) 2008-04-11 2015-08-06 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
WO2009132351A2 (en) * 2008-04-25 2009-10-29 University Of Medicine And Dentistry Of New Jersey Anti-sense microrna expression vectors
US9261508B2 (en) 2008-04-25 2016-02-16 Istituto Superiore Di Sanita Antisense RNA for treating cancer and inhibition of metastasis and vectors for antisense sequestration
US8916532B2 (en) 2008-04-28 2014-12-23 The Trustees Of The University Of Pennsylvania Methods for enhancing utrophin production via inhibition of microRNA
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
WO2009149318A2 (en) * 2008-06-05 2009-12-10 Research Foundation Of State University Of New York Mirnas as therapeutic targets in cancer
US8247388B2 (en) * 2008-06-06 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Role of miRNA in T cell leukemia
WO2009153774A2 (en) 2008-06-17 2009-12-23 Rosetta Genomics Ltd. Compositions and methods for prognosis of ovarian cancer
WO2010003420A2 (en) * 2008-06-17 2010-01-14 Gentofte Hospital Treatment of psoriasis and related diseases by mirna modulation
WO2010000665A1 (en) * 2008-06-30 2010-01-07 Santaris Pharma A/S Antidote oligomers
EP2310507A4 (en) * 2008-07-08 2013-03-20 David Gladstone Inst Methods and compositions for modulating angiogenesis
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
JP2012500199A (en) * 2008-08-11 2012-01-05 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Micro-RNA for promoting vascular integrity and uses thereof
WO2010022166A2 (en) * 2008-08-19 2010-02-25 Maine Institute For Human Genetics And Health Micro rna (mirna) and neurofibromatosis type 1 : a role in diagnosis and therapy
EP2447274B1 (en) * 2008-10-24 2017-10-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds and methods
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
US8263570B2 (en) * 2008-12-15 2012-09-11 National Taiwan University Treating picornavirus infection by targeting MicroRNA miR-141
CN102356162A (en) 2009-02-04 2012-02-15 得克萨斯系统大学董事会 Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders
US20120264806A1 (en) * 2009-02-06 2012-10-18 Bennett C Frank Oligomeric compounds and excipients
WO2010101951A1 (en) 2009-03-02 2010-09-10 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
US8735568B2 (en) 2009-03-09 2014-05-27 The J. David Gladstone Institutes Methods of modulating smooth muscle cell proliferation and differentiation
SG174455A1 (en) * 2009-03-19 2011-10-28 Agency Science Tech & Res Modulators of apoptosis and the uses thereof
EP2419538B1 (en) * 2009-04-16 2016-09-14 Padma Arunachalam Methods and compositions to detect and differentiate small rnas in rna maturation pathway
EP2421970B1 (en) * 2009-04-24 2016-09-07 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
WO2010133970A1 (en) 2009-05-20 2010-11-25 Eth Zurich Targeting micrornas for metabolic disorders
ES2618576T3 (en) 2009-05-28 2017-06-21 Curna, Inc. Treatment of diseases related to an antiviral gene by inhibiting a natural antisense transcript to an antiviral gene
ES2644055T3 (en) * 2009-06-05 2017-11-27 Centenary Institute Of Cancer Medicine And Cell Biology Therapeutic and diagnostic molecules
EP2440566A4 (en) * 2009-06-08 2013-10-16 Miragen Therapeutics CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
KR101885383B1 (en) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 Novel nucleic acid prodrugs and methods of use thereof
US9512164B2 (en) 2009-07-07 2016-12-06 Alnylam Pharmaceuticals, Inc. Oligonucleotide end caps
WO2011005942A2 (en) * 2009-07-08 2011-01-13 Idera Pharmaceuticals, Inc. Oligonucleotide-based compounds as inhibitors of toll-like receptors
WO2011011061A2 (en) * 2009-07-21 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
US8911940B2 (en) 2009-07-31 2014-12-16 The Translational Genomics Research Institute Methods of assessing a risk of cancer progression
US8815822B2 (en) * 2009-08-06 2014-08-26 Universiteit Maastricht Means and methods for counteracting, delaying and/or preventing adverse energy metabolism switches in heart disease
US20110190372A1 (en) 2009-08-07 2011-08-04 New York University Compositions and methods for treating inflammatory disorders
US8796238B2 (en) 2009-09-17 2014-08-05 Sigma-Aldrich Co. Llc Short RNA mimetics
EP2327783A1 (en) * 2009-11-27 2011-06-01 Universitätsklinikum Freiburg Pharmaceutical composition comprising miRNA-100 and its use in the modulation of blood vessel growth
US20120282326A1 (en) * 2009-12-16 2012-11-08 The University Of Western Ontario Compositions and methods related to mirna in diabetic conditions
WO2011088309A1 (en) 2010-01-14 2011-07-21 Regulus Therapeutics Inc. Microrna compositions and methods
WO2011094580A2 (en) 2010-01-28 2011-08-04 Alnylam Pharmaceuticals, Inc. Chelated copper for use in the preparation of conjugated oligonucleotides
WO2011097614A1 (en) * 2010-02-08 2011-08-11 Isis Pharmaceuticals, Inc. Mehods and compositions useful in diseases or conditions related to repeat expansion
AU2011219029B2 (en) * 2010-02-26 2017-02-02 Columbia University Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets
ES2743600T3 (en) 2010-03-12 2020-02-20 Brigham & Womens Hospital Inc Methods of treatment of vascular inflammatory disorders
WO2011117353A1 (en) * 2010-03-24 2011-09-29 Mirrx Therapeutics A/S Bivalent antisense oligonucleotides
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
WO2011130371A1 (en) 2010-04-13 2011-10-20 Life Technologies Corporation Compositions and methods for inhibition of nucleic acids function
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
WO2011133876A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US20130260460A1 (en) 2010-04-22 2013-10-03 Isis Pharmaceuticals Inc Conformationally restricted dinucleotide monomers and oligonucleotides
WO2011133918A1 (en) * 2010-04-23 2011-10-27 Isis Pharmaceuticals, Inc. Modulation of gm3 synthase (gm3s) expression
US9127033B2 (en) 2010-04-28 2015-09-08 Isis Pharmaceuticals, Inc. 5′ modified nucleosides and oligomeric compounds prepared therefrom
EP3173419A1 (en) 2010-04-28 2017-05-31 Ionis Pharmaceuticals, Inc. Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
EP2566964B1 (en) * 2010-05-07 2016-10-19 Centre National De La Recherche Scientifique Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
US20130210883A1 (en) 2010-05-21 2013-08-15 Johannes Grillari Lipase inhibitors
CA2800018C (en) 2010-05-21 2021-09-28 Universitaet Fuer Bodenkultur Wien Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders
US20130236968A1 (en) 2010-06-21 2013-09-12 Alnylam Pharmaceuticals, Inc. Multifunctional copolymers for nucleic acid delivery
NZ719520A (en) 2010-07-06 2017-07-28 Int Tech Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
ES2573669T3 (en) * 2010-07-08 2016-06-09 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for diabetes
WO2012009578A2 (en) * 2010-07-14 2012-01-19 The Curators Of The University Of Missouri Nanopore-facilitated single molecule detection of nucleic acids
US8815826B2 (en) 2010-07-23 2014-08-26 Regulus Therapeutics, Inc. Targeting microRNAs for the treatment of fibrosis
EP2608812B1 (en) 2010-08-25 2018-08-15 The General Hospital Corporation Nucleic acids targeting mir-33 micrornas for regulating lipid metabolism
US20130150431A1 (en) 2010-08-27 2013-06-13 New York University Mir-33 inhibitors and uses thereof
KR101235256B1 (en) * 2010-09-13 2013-02-21 서울대학교산학협력단 Treatment of Neurodegenerative Diseases by Targeting a miRNA
US20130210901A1 (en) * 2010-09-20 2013-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating neurodegenerative diseases
JP5868324B2 (en) 2010-09-24 2016-02-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ Asymmetric auxiliary group
US8933051B2 (en) 2010-09-30 2015-01-13 University Of Zurich Treatment of B-cell lymphoma with microRNA
US8951983B2 (en) 2010-10-17 2015-02-10 Yeda Research And Development Co. Ltd. Methods and compositions for the treatment of insulin-associated medical conditions
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
DK2638163T3 (en) 2010-11-12 2017-07-24 Massachusetts Gen Hospital POLYCOMB-ASSOCIATED NON-CODING RNAs
SG190355A1 (en) 2010-12-15 2013-07-31 Miragen Therapeutics Microrna inhibitors comprising locked nucleotides
US9308217B2 (en) * 2010-12-20 2016-04-12 Agency For Science, Technology And Research Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138
US8883757B2 (en) * 2011-01-03 2014-11-11 Rosetta Genomics Ltd. Compositions and methods for treatment of ovarian cancer
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
MY165507A (en) 2011-02-03 2018-03-28 Mirna Therapeutics Inc Synthetic mimics of mir-34
EP2670849A1 (en) 2011-02-03 2013-12-11 Mirna Therapeutics, Inc. Synthetic mimics of mir-124
GB201102283D0 (en) * 2011-02-09 2011-03-23 Ucl Business Plc Treatment
US9132152B2 (en) * 2011-02-10 2015-09-15 The Regents Of The University Of California Compositions and methods for generating induced pluripotent stem cells
CN102643808B (en) * 2011-02-18 2016-01-20 中国科学院上海药物研究所 The antisense oligonucleotide of people miR-1539 and application thereof
US8420617B2 (en) 2011-03-11 2013-04-16 Biocell Laboratories Multiantivirus compound, composition and method for treatment of virus diseases
WO2012140234A1 (en) * 2011-04-13 2012-10-18 Vib Vzw Modulation of mirna in diseases with aberrant angiogenesis
MY187685A (en) * 2011-04-25 2021-10-11 Sanofi Sa Microrna compounds and methods for modulating mir-21 activity
US9241950B2 (en) 2011-04-28 2016-01-26 New York University MiR-33 inhibitors and uses thereof to decrease inflammation
CA2835568A1 (en) * 2011-05-09 2012-11-15 The University Court Of The University Of Glasgow Methods of modulating micrornas in the treatment of pulmonary arterial hypertension
EP2525223A1 (en) * 2011-05-19 2012-11-21 Universiteit Maastricht In vitro method for predicting in vivo genotoxicity of chemical compounds.
WO2012177565A2 (en) * 2011-06-20 2012-12-27 California Institute Of Technology Regulation of macrophage activation using mir - 125b
US20140275211A1 (en) 2011-06-21 2014-09-18 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
EP2723863A1 (en) 2011-06-23 2014-04-30 Stella ApS Hcv combination therapy
US20140194491A1 (en) * 2011-06-24 2014-07-10 Syddansk Universitet Modulation of microrna-138 for the treatment of bone loss
WO2013000856A1 (en) 2011-06-30 2013-01-03 Santaris Pharma A/S Hcv combination therapy
JP2014520772A (en) 2011-06-30 2014-08-25 ステラ・アンパルトセルスカブ HCV combination therapy
DK2734208T3 (en) 2011-07-19 2017-06-19 Wave Life Sciences Ltd PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS
WO2013032962A2 (en) * 2011-08-28 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University Micro rnas to treat stroke, ischemic brain injury, traumatic brain injury, and neurodegenerative disease
US20140255353A1 (en) * 2011-08-29 2014-09-11 University Of Miami Compositions, kits and methods for treating obesity, diabetes and hyperglycemia
EP2751271A1 (en) * 2011-08-31 2014-07-09 Universität Zürich Prorektorat MNW Modulators of mir-323-3p for the prevention or treatment of rheumatoid arthritis
WO2013033627A2 (en) * 2011-09-01 2013-03-07 The Regents Of The University Of California Diagnosis and treatment of arthritis using epigenetics
ES2651515T3 (en) * 2011-09-06 2018-01-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. The miRNA-212/132 family as a therapeutic target
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
DK2756080T3 (en) 2011-09-14 2019-05-20 Translate Bio Ma Inc MULTIMERIC OILONCLEOTID CONNECTIONS
CA2850258A1 (en) 2011-09-28 2013-04-04 Royal College Of Surgeons In Ireland Inhibition of microrna-134 for the treatment of seizure-related disorders and neurologic injuries
US9428749B2 (en) 2011-10-06 2016-08-30 The Board Of Regents, The University Of Texas System Control of whole body energy homeostasis by microRNA regulation
EP2766482B1 (en) 2011-10-11 2016-12-07 The Brigham and Women's Hospital, Inc. Micrornas in neurodegenerative disorders
GB201117482D0 (en) * 2011-10-11 2011-11-23 Univ Dundee Targetiing of miRNA precursors
US10202643B2 (en) 2011-10-31 2019-02-12 University Of Utah Research Foundation Genetic alterations in glioma
IN2014DN03464A (en) 2011-11-03 2015-06-05 Dcb Usa Llc
DK2776590T3 (en) 2011-11-07 2016-12-05 Roche Innovation Ct Copenhagen As Prognostic method of assessing the efficacy of MICRO-RNA-122 inhibitors for HCV + patients
ES2923787T3 (en) 2011-11-18 2022-09-30 Alnylam Pharmaceuticals Inc Modified RNAi Agents
CN104302767A (en) * 2011-12-10 2015-01-21 俄亥俄州国家创新基金会 Mirnas useful to reduce lung cancer tumorigenesis and chemotherapy resistance and related compositons and methods
CA2859387A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
PL398211A1 (en) * 2012-02-22 2013-09-02 Instytut Chemii Bioorganicznej Polskiej Akademii Nauk RNA oligomer, method for regulating the process of creation the miRNA and the use of RNA re oligomers as regulators of the miRNA formation process
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
CN104411338A (en) 2012-04-02 2015-03-11 现代治疗公司 Modified polynucleotides for the production of biologics and proteins associated with human disease
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
KR102118429B1 (en) 2012-04-25 2020-06-03 사노피 Microrna compounds and methods for modulating mir-21 activity
US9334498B2 (en) 2012-05-10 2016-05-10 Uab Research Foundation Methods and compositions for modulating MIR-204 activity
US20150152410A1 (en) 2012-05-16 2015-06-04 Rana Therapeutics, Inc. Compositions and methods for modulating mecp2 expression
CA2873809A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
CA2873766A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating atp2a2 expression
US10059941B2 (en) 2012-05-16 2018-08-28 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
WO2013173645A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating utrn expression
AU2013262700A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating hemoglobin gene family expression
US9163235B2 (en) * 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
DK3354734T3 (en) 2012-06-21 2020-06-29 Miragen Therapeutics Inc Oligonucleotide-Based Inhibitors Comprehensive Locked Nucleic Acid Patterns
KR101850319B1 (en) 2012-07-13 2018-04-20 웨이브 라이프 사이언시스 리미티드 Asymmetric auxiliary group
CN104661664B (en) 2012-07-13 2020-07-03 波涛生命科学有限公司 Chiral control
CN104684923B (en) 2012-07-13 2018-09-28 株式会社新日本科学 Chiral Nuclec acid adjuvants
EP3195869B1 (en) 2012-07-27 2021-09-29 Agency for Science, Technology and Research (A*STAR) Method of promoting wound healing
JP2015529469A (en) 2012-09-14 2015-10-08 ラナ セラピューティクス インコーポレイテッド Multimeric oligonucleotide compounds
UA116639C2 (en) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Methods for treatment of alport syndrome
US9493838B2 (en) 2012-10-10 2016-11-15 Beth Israel Deaconess Medical Center, Inc. Biomarkers and treatments for heart failure
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
CA2889596C (en) 2012-11-15 2022-08-23 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chemically modified mRNA
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
WO2014113089A2 (en) 2013-01-17 2014-07-24 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
EP2759595B1 (en) * 2013-01-24 2016-09-14 Pierre Fabre Médicament S.A.S. Composition comprising an encapsulated antagomir
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
SG11201505387PA (en) 2013-01-30 2015-08-28 Hoffmann La Roche Lna oligonucleotide carbohydrate conjugates
EP3889173B1 (en) 2013-02-15 2023-07-05 Bioverativ Therapeutics Inc. Optimized factor viii gene
US20160022840A1 (en) * 2013-03-09 2016-01-28 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014160358A1 (en) * 2013-03-14 2014-10-02 Thomas Cooper Woods Use of mir-221 and 222 lowering agents to prevent cardiovascular disease in diabetic subjects
US9522130B2 (en) * 2013-03-14 2016-12-20 Thomas Cooper Woods Use of miR-221 and 222 lowering agents to prevent cardiovascular disease in diabetic subjects
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014140856A2 (en) 2013-03-15 2014-09-18 Graham Lord Mir-142 and antagonists thereof for treating disease
US20140309278A1 (en) 2013-03-15 2014-10-16 Mirna Therapeutics, Inc. Combination cancer treatments utilizing micrornas and egfr-tki inhibitors
JP6410791B2 (en) 2013-03-15 2018-10-24 ミラゲン セラピューティクス， インコーポレイテッド Locked nucleic acid inhibitor of MIR-145 and use thereof
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
EP2970909A4 (en) 2013-03-15 2017-02-15 The University of Chicago Methods and compositions related to t-cell activity
WO2014144217A1 (en) 2013-03-15 2014-09-18 The Curators Of The University Of Missouri Encoded nanopore sensor for multiplex nucleic acids detection
SG10201803157XA (en) 2013-05-01 2018-05-30 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
EP2992096B1 (en) 2013-05-01 2021-03-03 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
US10053690B2 (en) 2013-06-12 2018-08-21 New York University Anti-miR-27b and anti-miR-148a oligonucleotides as therapeutic tools for treating dyslipidemias and cardiovascular diseases
CN105473742A (en) * 2013-06-24 2016-04-06 米尔纳疗法公司 Biomarkers of miR-34 activity
ES2770667T3 (en) 2013-06-27 2020-07-02 Roche Innovation Ct Copenhagen As Antisense and conjugated oligomers that target PCSK9
CN103272248B (en) * 2013-06-28 2016-03-30 上海市内分泌代谢病研究所 The application of miR-15b in preparation treatment of diabetes preparation
LT3019619T (en) 2013-07-11 2021-12-10 Modernatx, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
CA2921459A1 (en) 2013-08-16 2015-02-19 Rana Therapeutics, Inc. Oligonucleotides targeting euchromatin regions of genes
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US20160369271A1 (en) * 2013-09-17 2016-12-22 Hocuslocus, Llc Methods of using structurally interacting rna
WO2015042447A1 (en) 2013-09-20 2015-03-26 Isis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
US9550989B2 (en) * 2013-10-03 2017-01-24 Washington University Rational design of microRNA-siRNA chimeras for multi-functional target suppression
EA201690675A1 (en) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
LT3052628T (en) 2013-10-04 2020-09-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the alas1 gene
GB201318492D0 (en) * 2013-10-18 2013-12-04 Academisch Ziekenhuis Leiden A U Leiden Uni Medical Ctr Vascular re-modelling
EP3060664B1 (en) 2013-10-25 2021-07-07 Sanofi Microrna compounds and methods for modulating mir-21 activity
US9458458B2 (en) * 2013-11-11 2016-10-04 Emory University Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto
JPWO2015108047A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant having immunity induction activity and immunity induction activator
JPWO2015108048A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant and antitumor agent having antitumor activity
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
SG10201912897UA (en) 2014-01-16 2020-02-27 Wave Life Sciences Ltd Chiral design
JP2017506638A (en) 2014-02-14 2017-03-09 ザ チルドレンズ ホスピタル オブ フィラデルフィア Compositions and methods for treating liver injury
US10280418B2 (en) 2014-03-18 2019-05-07 Univeristy Of Massachusetts RAAV-based compositions and methods for treating amyotrophic lateral sclerosis
PT3757214T (en) 2014-04-01 2022-08-26 Biogen Ma Inc Compositions for modulating sod-1 expression
US10335500B2 (en) 2014-05-12 2019-07-02 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
JP6763780B2 (en) 2014-05-12 2020-09-30 ザ・ジョンズ・ホプキンス・ユニバーシティー Manipulation of synthetic brain penetrating gene vectors
US10323067B2 (en) * 2014-05-14 2019-06-18 Evorx Technologies, Inc. Methods and compositions for controlling gene expression and treating cancer
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
DK3155120T5 (en) * 2014-06-13 2019-01-28 Univ Wien Bodenkultur Procedures for diagnosing bone fractures and disorders
US20150368648A1 (en) * 2014-06-20 2015-12-24 Yale University Compositions and methods of inhibiting gene expression in a lung
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
US10472626B2 (en) * 2014-07-31 2019-11-12 Agency For Science, Technology And Research Modified antimir-138 oligonucleotides
KR20170033439A (en) 2014-08-07 2017-03-24 레굴루스 테라퓨틱스 인크 Targeting micrornas for metabolic disorders
EP3808846A1 (en) 2014-08-20 2021-04-21 Alnylam Pharmaceuticals, Inc. Modified double-stranded rna agents
US9376681B2 (en) * 2014-09-08 2016-06-28 MiRagen Therapeutics, Inc. miR-29 mimics and uses thereof
US10174320B2 (en) 2014-09-21 2019-01-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Downregulating miR-132 for the treatment of lipid related disorders
JP6342288B2 (en) * 2014-10-08 2018-06-13 学校法人帝京大学 miR-96-5p inhibitor and screening method thereof
US10858650B2 (en) 2014-10-30 2020-12-08 The General Hospital Corporation Methods for modulating ATRX-dependent gene repression
MX2017005834A (en) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease.
EP3461904A1 (en) 2014-11-10 2019-04-03 ModernaTX, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
MX2017006216A (en) 2014-11-14 2018-08-29 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als).
CN112410339A (en) 2014-11-14 2021-02-26 沃雅戈治疗公司 Regulatory polynucleotides
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
WO2016115503A1 (en) 2015-01-16 2016-07-21 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
WO2016118612A2 (en) 2015-01-20 2016-07-28 MiRagen Therapeutics, Inc. Mir-92 inhibitors and uses thereof
US10758558B2 (en) 2015-02-13 2020-09-01 Translate Bio Ma, Inc. Hybrid oligonucleotides and uses thereof
US9840709B2 (en) * 2015-02-20 2017-12-12 Rosalind Franklin University Of Medicine And Science Antisense compounds targeting genes associated with cystic fibrosis
US10525076B2 (en) 2015-02-20 2020-01-07 Rosalind Franklin University Of Medicine And Science Antisense compounds targeting genes associated with cystic fibrosis
CN107250378B (en) * 2015-02-24 2021-09-03 特里奥科技株式会社 Method for diagnosis, prevention and treatment of brain metastasis of cancer, and drug delivery system for crossing blood brain barrier
WO2016149370A1 (en) * 2015-03-16 2016-09-22 MiRagen Therapeutics, Inc. Mirna mimetics and their use in treating sensory conditions
WO2016149455A2 (en) 2015-03-17 2016-09-22 The General Hospital Corporation The rna interactome of polycomb repressive complex 1 (prc1)
US20160291826A1 (en) * 2015-03-30 2016-10-06 Nemrude Verzano STANDALONE AND DISTRIBUTED APPLICATION FOR SIMULATION OF INTERNET OF THINGS (IoT) SCENARIOS
KR101734645B1 (en) * 2015-05-18 2017-05-11 (주)에이엔티랩스 Method for diagnosis of early alzheimers disease or mild cognitive impairment
US10787664B2 (en) * 2015-05-26 2020-09-29 City Of Hope Compounds of chemically modified oligonucleotides and methods of use thereof
RU2718534C2 (en) 2015-06-05 2020-04-08 Мираджен Терапьютикс, Инк. Mir-155 inhibitors for treatment of cutaneous t-cell lymphoma (ctcl)
CA3205381A1 (en) * 2015-07-17 2017-01-26 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
WO2017021963A1 (en) 2015-08-03 2017-02-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases
EP3331535A4 (en) * 2015-08-05 2019-03-13 Centenary Institute Of Cancer Medicine And Cell Biology Methods for treating tumours
CA3033617A1 (en) 2015-08-11 2017-02-16 Anie Philip Peptidic tgf-beta antagonists
WO2017027839A1 (en) 2015-08-13 2017-02-16 Somagenics, Inc. Methods and compositions of short small hairpin rnas and micrornas for wound healing
MA44836A (en) 2015-08-26 2018-07-04 Univ Texas KIDNEY POLYCYSTIC SYNDROME TREATMENT METHODS
DK3350333T3 (en) 2015-09-17 2022-01-31 Modernatx Inc POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION
AU2016336344A1 (en) 2015-10-05 2018-04-19 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
WO2017066594A1 (en) * 2015-10-16 2017-04-20 Rana Therapeutics, Inc. Methods for identifying and targeting non-coding rna scaffolds
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
US11001622B2 (en) 2015-11-19 2021-05-11 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
EP3181698A1 (en) 2015-12-16 2017-06-21 European Molecular Biology Laboratory (EMBL) Microrna mir-142 as stem cell marker
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
ES2926585T3 (en) 2016-02-01 2022-10-27 Bioverativ Therapeutics Inc Optimized Factor VIII genes
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2017187426A1 (en) * 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CA3024625A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding citrin for the treatment of citrullinemia type 2
JP7114485B2 (en) 2016-05-18 2022-08-08 モデルナティエックス インコーポレイテッド Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
EP3458105B1 (en) 2016-05-18 2024-01-17 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
EP3458589A4 (en) 2016-05-18 2020-01-01 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
CA3024470A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding interleukin-12 (il12) and uses thereof
EP3458104A1 (en) 2016-05-18 2019-03-27 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
US20190275170A1 (en) 2016-05-18 2019-09-12 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
WO2017201332A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
AU2017286606A1 (en) 2016-06-14 2018-12-13 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11564997B2 (en) 2016-06-29 2023-01-31 Crispr Therapeutics Ag Materials and methods for treatment of friedreich ataxia and other related disorders
EP3478313B1 (en) 2016-06-29 2022-05-04 CRISPR Therapeutics AG Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
US11427838B2 (en) 2016-06-29 2022-08-30 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
CN109843914B (en) 2016-07-06 2024-03-15 沃泰克斯药物股份有限公司 Materials and methods for treating pain-related disorders
US11801313B2 (en) 2016-07-06 2023-10-31 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
WO2018017483A1 (en) * 2016-07-18 2018-01-25 Jaan Biotherapeutics, Llc Compositions and methods for treatment of cardiac diseases
AR109207A1 (en) 2016-08-05 2018-11-07 Syngenta Participations Ag PATHOPE CONTROL OF COLEOPTERS USING RNA MOLECULES
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US11337994B2 (en) 2016-09-15 2022-05-24 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
ES2659845B1 (en) * 2016-09-19 2019-01-04 Univ Valencia Modulation of microRNAs against myotonic dystrophy type 1 and antagonists of microRNAs for this
JP2019532657A (en) 2016-10-26 2019-11-14 モデルナティーエックス， インコーポレイテッド Messenger ribonucleic acid for enhancing immune response and method of use thereof
BR112019008810A2 (en) * 2016-11-01 2019-07-16 Univ New York State Res Found 5-halouracil modified microplates and their use in cancer treatment
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
BR112019009434A2 (en) * 2016-11-11 2019-07-30 Univ Tennessee Res Found biomarkers for early embryonic viability and methods for it
CN106474549B (en) * 2016-11-21 2019-05-03 南通大学 The novel tissue tissue-engineered nerve of MicroRNA gene mediated constructs and its in the application for repairing neurologic defect
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
CN110753758A (en) 2016-12-22 2020-02-04 俄亥俄州国家创新基金会 Compositions and methods for reprogramming somatic cells to induced angiogenic cells
US11214839B2 (en) 2017-01-09 2022-01-04 Dana-Farber Cancer Institute, Inc. Circulating microRNA signatures for ovarian cancer
BR112019015797A2 (en) 2017-02-01 2020-03-17 Modernatx, Inc. IMMUNOMODULATORY THERAPEUTIC MRNA COMPOSITIONS THAT CODE ACTIVATING ONCOGEN MUTATION PEPTIDES
WO2018154459A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
WO2018154462A2 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
US11559588B2 (en) 2017-02-22 2023-01-24 Crispr Therapeutics Ag Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
JP2020508056A (en) 2017-02-22 2020-03-19 クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡＧ Compositions and methods for gene editing
WO2018154418A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
SG11201906297QA (en) 2017-03-24 2019-10-30 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
US11845935B2 (en) 2017-03-29 2023-12-19 Children's Hospital Medical Center Regulation of MIR-143 using nucleic acid molecules
AU2018253115B2 (en) 2017-04-12 2022-08-11 Edigene Biotechnology, Inc. Aryl hydrocarbon receptor antagonists and uses thereof
WO2018195486A1 (en) 2017-04-21 2018-10-25 The Broad Institute, Inc. Targeted delivery to beta cells
WO2018200788A1 (en) * 2017-04-26 2018-11-01 Beryllium, Llc Oligonucleotide binding agents
WO2018201160A1 (en) 2017-04-28 2018-11-01 Agrospheres, Inc. Compositions and methods for enzyme immobilization
AU2018256925A1 (en) 2017-04-28 2019-10-10 Agrospheres, Inc. Compositions and methods for the encapsulation and scalable delivery of agrochemicals
US11603542B2 (en) 2017-05-05 2023-03-14 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
WO2018208972A1 (en) 2017-05-09 2018-11-15 University Of Massachusetts Methods of treating amyotrophic lateral sclerosis (als)
WO2018213789A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Modified messenger rna comprising functional rna elements
WO2018213731A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
US11230711B2 (en) 2017-08-14 2022-01-25 University Of North Texas Health Science Center Inhibition of LET7I as a means to enhance the protective effect of progesterone against stroke
CA3073211A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
US20200281174A1 (en) * 2017-09-08 2020-09-10 Ohio State Innovation Foundation Novel microrna inhibitor therapy in systemic lupus erythematosus
WO2019060686A1 (en) 2017-09-22 2019-03-28 University Of Massachusetts Sod1 dual expression vectors and uses thereof
EP3688168A4 (en) 2017-09-25 2021-07-14 Agrospheres, Inc. Compositions and methods for scalable production and delivery of biologicals
US10676744B2 (en) * 2017-10-13 2020-06-09 University Of South Carolina Modulation of adipose tissue macrophage phenotype by use of MicroRNA-30
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
EP3697908A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
WO2019089826A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
WO2019089833A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
US20190153440A1 (en) 2017-11-21 2019-05-23 Casebia Therapeutics Llp Materials and methods for treatment of autosomal dominant retinitis pigmentosa
EP3714048A1 (en) 2017-11-22 2020-09-30 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
MA50802A (en) 2017-11-22 2020-09-30 Modernatx Inc POLYNUCLEOTIDES CODING FOR ALPHA AND BETA SUB-UNITS OF PROPIONYL-COA CARBOXYLASE FOR THE TREATMENT OF PROPIONIC ACIDEMIA
WO2019113375A2 (en) 2017-12-06 2019-06-13 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
MA51155A (en) 2017-12-15 2020-10-21 Flagship Pioneering Innovations Vi Llc COMPOSITIONS CONSISTING OF CIRCULAR POLYRIBONUCLEOTIDES AND THEIR USES
CN108048551B (en) * 2017-12-20 2021-08-03 中国人民解放军第四军医大学 Application of miR-139-3p and antagonist thereof in diagnosis and treatment of bone system diseases
JP7402163B2 (en) 2017-12-21 2023-12-20 クリスパー セラピューティクス アーゲー Materials and methods for the treatment of Usher syndrome type 2A
CN113116918B (en) * 2017-12-29 2022-06-14 中国科学院上海药物研究所 Application of PCSK 9-targeted microRNA in treatment of LDLC-related metabolic diseases
CA3087527A1 (en) 2018-01-03 2019-07-11 Magenta Therapeutics, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
MA51523A (en) 2018-01-05 2020-11-11 Modernatx Inc POLYNUCLEOTIDES CODING ANTI-BODY ANTI-CHIKUNGUNYA VIRUS
US20190314291A1 (en) 2018-01-30 2019-10-17 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
JP7414237B2 (en) 2018-02-13 2024-01-16 東レ株式会社 Kits or devices and methods for the detection of dementia
EP3762500A1 (en) 2018-03-06 2021-01-13 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
CN108144061B (en) * 2018-03-13 2019-11-26 中南大学湘雅二医院 Application of the microRNA-210 inhibitor on preparation treatment inflammatory skin medicine
US20210163928A1 (en) 2018-04-11 2021-06-03 Modernatx, Inc. Messenger rna comprising functional rna elements
WO2019222444A2 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Directed evolution
WO2019222441A1 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
EP3793685A1 (en) 2018-05-18 2021-03-24 F. Hoffmann-La Roche AG Pharmaceutical compositions for treatment of microrna related diseases
US11332789B2 (en) * 2018-05-21 2022-05-17 Temple University-Of The Commonwealth System Of Higher Education Compositions and methods for diagnosing and treating hyperlipidemia-related diseases
WO2019232160A1 (en) * 2018-05-31 2019-12-05 Beth Israel Deaconess Medical Center Rna-aided immunotherapeutics
WO2019232548A2 (en) * 2018-06-01 2019-12-05 Children's National Medical Center Compositions and methods for treating and preventing muscular disorders and dystrophies, steroid side effects, and inflammation
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3817747A4 (en) 2018-07-02 2022-07-06 Aptamir Therapeutics, Inc. Targeted delivery of therapeutic agents to human adipocytes
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
WO2020038968A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Microrna-134 biomarker
MA53545A (en) 2018-09-02 2021-07-14 Modernatx Inc POLYNUCLEOTIDES ENCODED FOR VERY LONG CHAIN ACYL-COA DEHYDROGENASE FOR THE TREATMENT OF VERY LONG CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY
MA53609A (en) 2018-09-13 2021-07-21 Modernatx Inc POLYNUCLEOTIDES ENCODED GLUCOSE-6-PHOSPHATASE FOR THE TREATMENT OF GLYCOGENOSIS
MA53608A (en) 2018-09-13 2021-07-21 Modernatx Inc POLYNUCLEOTIDES ENCODED FOR THE E1-ALPHA, E1-BETA AND E2 SUBUNITS OF THE BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE COMPLEX FOR THE TREATMENT OF LEUCINOSIS
JP2022500444A (en) 2018-09-14 2022-01-04 モダーナティエックス・インコーポレイテッドModernaTX, Inc. A polynucleotide encoding polypeptide A1, a family of uridine diphosphate glycosyltransferases for the treatment of Crigler-Najer syndrome
WO2020056304A1 (en) 2018-09-14 2020-03-19 Modernatx, Inc. Methods and compositions for treating cancer using mrna therapeutics
EP3852728A1 (en) 2018-09-20 2021-07-28 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US20220152225A1 (en) 2018-09-27 2022-05-19 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
US11253495B2 (en) 2018-11-21 2022-02-22 Yanming Wang Pharmaceutical composition for treating excessive lactate production and acidemia
CN113453707A (en) 2018-12-21 2021-09-28 库瑞瓦格股份公司 RNA for malaria vaccine
JP2022523320A (en) * 2019-01-29 2022-04-22 ザ ジェネラル ホスピタル コーポレイション Oligonucleotides and methods for the treatment of age-related macular degeneration
CA3128215A1 (en) 2019-01-31 2020-08-06 Modernatx, Inc. Methods of preparing lipid nanoparticles
CA3125511A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
WO2020172198A1 (en) * 2019-02-18 2020-08-27 Duke University Prr-activating and microrna-inhibiting molecules and methods of using same
AU2020233404A1 (en) 2019-03-04 2021-09-16 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides and pharmaceutical compositions thereof
CN113661242A (en) 2019-03-25 2021-11-16 旗舰创业创新第六有限责任公司 Compositions comprising modified cyclic polyribonucleotides and uses thereof
CA3139321A1 (en) 2019-05-07 2020-11-12 Modernatx, Inc. Polynucleotides for disrupting immune cell activity and methods of use thereof
WO2020227537A1 (en) 2019-05-07 2020-11-12 Modernatx, Inc Differentially expressed immune cell micrornas for regulation of protein expression
WO2020227642A1 (en) 2019-05-08 2020-11-12 Modernatx, Inc. Compositions for skin and wounds and methods of use thereof
AU2020292427A1 (en) 2019-06-14 2022-01-06 Flagship Pioneering Innovations Vi, Llc Circular RNAs for cellular therapy
WO2020254535A1 (en) 2019-06-18 2020-12-24 Curevac Ag Rotavirus mrna vaccine
AU2020296190A1 (en) 2019-06-19 2022-01-06 Flagship Pioneering Innovations Vi, Llc Methods of dosing circular polyribonucleotides
EP3986469A1 (en) 2019-06-19 2022-04-27 Flagship Pioneering Innovations VI, LLC Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
EP3986480A1 (en) 2019-06-24 2022-04-27 ModernaTX, Inc. Messenger rna comprising functional rna elements and uses thereof
MA56539A (en) 2019-06-24 2022-04-27 Modernatx Inc ENDONUCLEASE RESISTANT MESSENGER RNA AND USES THEREOF
WO2020261227A1 (en) 2019-06-26 2020-12-30 Biorchestra Co., Ltd. Micellar nanoparticles and uses thereof
AU2020328855A1 (en) 2019-08-14 2022-03-03 CureVac SE RNA combinations and compositions with decreased immunostimulatory properties
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
EP4045076A1 (en) 2019-10-15 2022-08-24 ModernaTX, Inc. Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
WO2021087406A1 (en) 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
TW202142689A (en) 2020-01-29 2021-11-16 美商旗艦先鋒創新有限責任公司 Compositions for translation and methods of use thereof
US20230285297A1 (en) 2020-01-31 2023-09-14 Modernatx, Inc. Methods of preparing lipid nanoparticles
CA3160511A1 (en) 2020-02-04 2021-08-12 Susanne RAUCH Coronavirus vaccine
WO2021189390A1 (en) * 2020-03-27 2021-09-30 深圳先进技术研究院 Medicament for preventing/treating type 2 diabetes and uses
EP4149435A1 (en) 2020-05-14 2023-03-22 Modernatx, Inc. Lnp compositions comprising an mrna therapeutic and an effector molecule
CA3179420A1 (en) 2020-05-20 2021-11-25 Avak Kahvejian Coronavirus antigen compositions and their uses
US20230193311A1 (en) 2020-05-20 2023-06-22 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
WO2021236952A1 (en) 2020-05-20 2021-11-25 Flagship Pioneering, Inc. Compositions and methods for producing human polyclonal antibodies
EP3993828A1 (en) 2020-05-29 2022-05-11 CureVac AG Nucleic acid based combination vaccines
WO2021247507A1 (en) 2020-06-01 2021-12-09 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
AU2021297248A1 (en) 2020-06-23 2023-02-02 Modernatx, Inc. LNP compositions comprising mRNA therapeutics with extended half-life
US20230295257A1 (en) 2020-07-24 2023-09-21 Strand Therapeutics Inc. Lipid nanoparticle comprising modified nucleotides
TW202220637A (en) 2020-08-06 2022-06-01 美商現代公司 Methods of preparing lipid nanoparticles
US20240066114A1 (en) 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
AU2021336976A1 (en) 2020-09-03 2023-03-23 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
IL302625A (en) 2020-11-13 2023-07-01 Modernatx Inc Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
CN112458165A (en) * 2020-12-27 2021-03-09 中山大学孙逸仙纪念医院 Alzheimer disease prediction marker, detection kit and application
KR20230129479A (en) 2021-01-08 2023-09-08 스트랜드 세러퓨틱스 인코포레이티드 Expression constructs and uses thereof
WO2022159799A1 (en) * 2021-01-25 2022-07-28 Prevail Therapeutics, Inc. Modulation of aav-based gene expression
CA3170747A1 (en) 2021-01-27 2022-08-04 Moritz THRAN Method of reducing the immunostimulatory properties of in vitro transcribed rna
AU2022220328A1 (en) 2021-02-12 2023-08-17 Modernatx, Inc. Lnp compositions comprising payloads for in vivo therapy
IL304956A (en) 2021-02-12 2023-10-01 Merand Pharmaceuticals Inc Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
EP4046631A1 (en) * 2021-02-18 2022-08-24 Universitat de València Msi2 as a therapeutic target for the treatment of myotonic dystrophy
EP4308694A1 (en) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
RU2768154C1 (en) * 2021-03-23 2022-03-23 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московская государственная академия ветеринарной медицины и биотехнологии - МВА имени К.И. Скрябина" (ФГБОУ ВО МГАВМиБ - МВА имени К.И. Скрябина) Method for differential diagnosis of acute and chronic hepatitis in dogs based on cfa-mrna expression in blood serum
WO2022204370A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
EP4334446A1 (en) 2021-05-03 2024-03-13 CureVac SE Improved nucleic acid sequence for cell type specific expression
WO2022266083A2 (en) 2021-06-15 2022-12-22 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
CA3230056A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
WO2023056044A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023064469A1 (en) 2021-10-13 2023-04-20 Modernatx, Inc. Compositions of mrna-encoded il15 fusion proteins and methods of use thereof
CN113913532A (en) * 2021-10-25 2022-01-11 扬州大学 miRNA marker related to Hu sheep papilla cell proliferation and detection primer and application thereof
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2023183909A2 (en) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
WO2023196399A1 (en) 2022-04-06 2023-10-12 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
EP4282964A1 (en) * 2022-05-23 2023-11-29 Universitat de Valéncia Oligonucleotides conjugated to oleic acid and uses thereof
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2024008950A1 (en) * 2022-07-08 2024-01-11 Ospedale San Raffaele S.R.L. Transgene cassettes
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024026475A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
WO2024026482A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Lipid nanoparticle compositions comprising surface lipid derivatives and related uses
WO2024026487A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Lipid nanoparticle compositions comprising phospholipid derivatives and related uses

Family Cites Families (259)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
JPS5927900A (en) 1982-08-09 1984-02-14 Wakunaga Seiyaku Kk Oligonucleotide derivative and its preparation
FR2540122B1 (en) 1983-01-27 1985-11-29 Centre Nat Rech Scient NOVEL COMPOUNDS COMPRISING A SEQUENCE OF OLIGONUCLEOTIDE LINKED TO AN INTERCALATION AGENT, THEIR SYNTHESIS PROCESS AND THEIR APPLICATION
US4605735A (en) 1983-02-14 1986-08-12 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4824941A (en) 1983-03-10 1989-04-25 Julian Gordon Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
US4587044A (en) 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (en) 1984-07-19 1989-02-17 Centre Nat Rech Scient NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
US5258506A (en) 1984-10-16 1993-11-02 Chiron Corporation Photolabile reagents for incorporation into oligonucleotide chains
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
FR2575751B1 (en) 1985-01-08 1987-04-03 Pasteur Institut NOVEL ADENOSINE DERIVATIVE NUCLEOSIDES, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US4762779A (en) 1985-06-13 1988-08-09 Amgen Inc. Compositions and methods for functionalizing nucleic acids
US5317098A (en) 1986-03-17 1994-05-31 Hiroaki Shizuya Non-radioisotope tagging of fragments
JPS638396A (en) 1986-06-30 1988-01-14 Wakunaga Pharmaceut Co Ltd Poly-labeled oligonucleotide derivative
DE3788914T2 (en) 1986-09-08 1994-08-25 Ajinomoto Kk Compounds for cleaving RNA at a specific position, oligomers used in the preparation of these compounds and starting materials for the synthesis of these oligomers.
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
ATE113059T1 (en) 1987-06-24 1994-11-15 Florey Howard Inst NUCLEOSIDE DERIVATIVES.
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US5525465A (en) 1987-10-28 1996-06-11 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates and methods of production and applications of the same
DE3738460A1 (en) 1987-11-12 1989-05-24 Max Planck Gesellschaft MODIFIED OLIGONUCLEOTIDS
US5403711A (en) 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
JP3019994B2 (en) 1987-11-30 2000-03-15 ユニバーシティ オブ アイオワ リサーチ ファウンデーション Novel oligodeoxynucleotide, method of blocking expression of target gene using the same, and novel oligodeoxynucleotide and method of inhibiting expression of target gene using the same
US5082830A (en) 1988-02-26 1992-01-21 Enzo Biochem, Inc. End labeled nucleotide probe
EP0406309A4 (en) 1988-03-25 1992-08-19 The University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5109124A (en) 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5262536A (en) 1988-09-15 1993-11-16 E. I. Du Pont De Nemours And Company Reagents for the preparation of 5'-tagged oligonucleotides
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5512439A (en) 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5599923A (en) 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5451463A (en) 1989-08-28 1995-09-19 Clontech Laboratories, Inc. Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5254469A (en) 1989-09-12 1993-10-19 Eastman Kodak Company Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5721218A (en) 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
AU658562B2 (en) 1989-10-24 1995-04-27 Isis Pharmaceuticals, Inc. 2' modified oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5292873A (en) 1989-11-29 1994-03-08 The Research Foundation Of State University Of New York Nucleic acids labeled with naphthoquinone probe
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5486603A (en) 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5623065A (en) 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
AU7579991A (en) 1990-02-20 1991-09-18 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
EP0745689A3 (en) 1990-05-11 1996-12-11 Microprobe Corporation A dipstick for a nucleic acid hybridization assay
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
BR9106702A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc ANALOG OF OLIGONUCLEOTIDEOS AND PROCESSES TO MODULATE THE PRODUCTION OF A PROTEIN BY AN ORGANISM AND TO TREAT AN ORGANISM
US5223618A (en) 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5688941A (en) 1990-07-27 1997-11-18 Isis Pharmaceuticals, Inc. Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
CA2088673A1 (en) 1990-08-03 1992-02-04 Alexander L. Weis Compounds and methods for inhibiting gene expression
US5591720A (en) 1990-08-16 1997-01-07 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating the effects of cytomegalovirus infections
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
EP0549686A4 (en) 1990-09-20 1995-01-18 Gilead Sciences Inc Modified internucleoside linkages
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
CA2095212A1 (en) 1990-11-08 1992-05-09 Sudhir Agrawal Incorporation of multiple reporter groups on synthetic oligonucleotides
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
JP3220180B2 (en) 1991-05-23 2001-10-22 三菱化学株式会社 Drug-containing protein-bound liposomes
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5371241A (en) 1991-07-19 1994-12-06 Pharmacia P-L Biochemicals Inc. Fluorescein labelled phosphoramidites
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
EP0538194B1 (en) 1991-10-17 1997-06-04 Novartis AG Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
DK1695979T3 (en) 1991-12-24 2011-10-10 Isis Pharmaceuticals Inc Gapped modified oligonucleotides
US5595726A (en) 1992-01-21 1997-01-21 Pharmacyclics, Inc. Chromophore probe for detection of nucleic acid
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
FR2687679B1 (en) 1992-02-05 1994-10-28 Centre Nat Rech Scient OLIGOTHIONUCLEOTIDES.
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
FR2692265B1 (en) 1992-05-25 1996-11-08 Centre Nat Rech Scient BIOLOGICALLY ACTIVE COMPOUNDS OF THE PHOSPHOTRIESTER TYPE.
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
EP0577558A2 (en) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
US5272250A (en) 1992-07-10 1993-12-21 Spielvogel Bernard F Boronated phosphoramidate compounds
ATE282695T1 (en) 1992-07-20 2004-12-15 Isis Pharmaceuticals Inc PSEUDO HALF-KNOT FORMING RNA THROUGH HYBRIDIZATION OF ANTISESEOLIGON NUCLEOTIDES TO TARGETED RNA SECONDARY STRUCTURES
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
AU678769B2 (en) 1992-07-27 1997-06-12 Hybridon, Inc. Oligonucleotide alkylphosphonothioates
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
JP3351476B2 (en) 1993-01-22 2002-11-25 三菱化学株式会社 Phospholipid derivatives and liposomes containing the same
CN1121721A (en) 1993-01-25 1996-05-01 海布里顿公司 Oligonucleotido alky phosphate and alky substituted phosphate
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
DE69424406T2 (en) 1993-02-19 2000-10-26 Nippon Shinyaku Co Ltd MEDICINAL COMPOSITION CONTAINING A NUCLEIC ACID COPOLYMER
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
GB9304620D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Compounds
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
DK0691968T3 (en) 1993-03-30 1998-02-23 Sanofi Sa Acyclic nucleoside analogs and oligonucleotide sequences containing these
JPH08508491A (en) 1993-03-31 1996-09-10 スターリング ウインスロップ インコーポレイティド Oligonucleotides with phosphodiester bonds replaced by amide bonds
DE4311944A1 (en) 1993-04-10 1994-10-13 Degussa Coated sodium percarbonate particles, process for their preparation and detergent, cleaning and bleaching compositions containing them
US5462854A (en) 1993-04-19 1995-10-31 Beckman Instruments, Inc. Inverse linkage oligonucleotides for chemical and enzymatic processes
FR2705099B1 (en) 1993-05-12 1995-08-04 Centre Nat Rech Scient Phosphorothioate triester oligonucleotides and process for their preparation.
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5614621A (en) 1993-07-29 1997-03-25 Isis Pharmaceuticals, Inc. Process for preparing oligonucleotides using silyl-containing diamino phosphorous reagents
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
ATE196311T1 (en) 1993-12-09 2000-09-15 Univ Jefferson COMPOUNDS AND METHODS FOR SITE-SPECIFIC MUTATION IN EUKARYOTIC CELLS
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5646269A (en) 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5597696A (en) 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
PT739898E (en) 1995-03-13 2002-03-28 Aventis Pharma Gmbh PHOSPHONUCLETIC ACID MONO-ESTERS PROCESS FOR PREPARING AND USING
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
US5705621A (en) 1995-11-17 1998-01-06 Isis Pharmaceuticals, Inc. Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same
AU1430097A (en) 1996-01-16 1997-08-11 Ribozyme Pharmaceuticals, Inc. Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US20040203024A1 (en) * 1996-06-06 2004-10-14 Baker Brenda F. Modified oligonucleotides for use in RNA interference
US5760209A (en) 1997-03-03 1998-06-02 Isis Pharmaceuticals, Inc. Protecting group for synthesizing oligonucleotide analogs
JP3756313B2 (en) 1997-03-07 2006-03-15 武 今西 Novel bicyclonucleosides and oligonucleotide analogues
EP1557424A1 (en) 1997-09-12 2005-07-27 Exiqon A/S Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6007992A (en) 1997-11-10 1999-12-28 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US6028183A (en) 1997-11-07 2000-02-22 Gilead Sciences, Inc. Pyrimidine derivatives and oligonucleotides containing same
US6020475A (en) 1998-02-10 2000-02-01 Isis Pharmeuticals, Inc. Process for the synthesis of oligomeric compounds
US6326478B1 (en) 1998-07-08 2001-12-04 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6169177B1 (en) 1998-11-06 2001-01-02 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomeric compounds
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6121000A (en) * 1999-02-11 2000-09-19 Genesense Technologies, Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
CN1273478C (en) 1999-02-12 2006-09-06 三共株式会社 Novel nucleosides and oligonucleotide analogues
WO2000050050A1 (en) 1999-02-23 2000-08-31 Isis Pharmaceuticals, Inc. Multiparticulate formulation
US6121437A (en) 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
CN102180924A (en) 1999-05-04 2011-09-14 桑塔里斯制药公司 L-ribo-LNA analogues
US6147200A (en) 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
EP1224280A2 (en) 1999-10-04 2002-07-24 Exiqon A/S Design of high affinity rnase h recruiting oligonucleotide
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
AU2001245793A1 (en) * 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
US6258601B1 (en) * 2000-09-07 2001-07-10 Isis Pharmaceuticals, Inc. Antisense modulation of ubiquitin protein ligase expression
US6329203B1 (en) * 2000-09-08 2001-12-11 Isis Pharmaceuticals, Inc. Antisense modulation of glioma-associated oncogene-1 expression
US6426220B1 (en) 2000-10-30 2002-07-30 Isis Pharmaceuticals, Inc. Antisense modulation of calreticulin expression
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US20050256068A1 (en) 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
WO2002097134A2 (en) 2001-05-25 2002-12-05 Isis Pharmaceuticals, Inc. Modified peptide nucleic acid
WO2003004602A2 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US20030175906A1 (en) 2001-07-03 2003-09-18 Muthiah Manoharan Nuclease resistant chimeric oligonucleotides
US20030158403A1 (en) 2001-07-03 2003-08-21 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
ITBS20010079U1 (en) * 2001-09-24 2003-03-24 Rib Srl ELECTROMECHANICAL BARRIER
EP2385122B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
ATE519774T1 (en) 2002-02-20 2011-08-15 Sirna Therapeutics Inc RNA DISRUPTION-MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION WITH SHORT INTERFERING NUCLEIC ACID (SINA)
US20040053876A1 (en) * 2002-03-26 2004-03-18 The Regents Of The University Of Michigan siRNAs and uses therof
US7737264B2 (en) 2002-04-05 2010-06-15 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation HIF-1α expression
PT1504126E (en) * 2002-05-03 2014-06-02 Univ Duke A method of regulating gene expression
US20030228691A1 (en) * 2002-05-17 2003-12-11 Lewis David L. Processes for inhibiting gene expression using polynucleotides
WO2004001013A2 (en) * 2002-06-24 2003-12-31 Baylor College Of Medicine Inhibition of gene expression in vertebrates using double-stranded rna (rnai)
EP1857547B2 (en) * 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
US20040058886A1 (en) * 2002-08-08 2004-03-25 Dharmacon, Inc. Short interfering RNAs having a hairpin structure containing a non-nucleotide loop
JP4939055B2 (en) 2002-11-13 2012-05-23 トマス ジェファソン ユニバーシティ Compositions and methods for diagnosis and treatment of cancer
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
ATE411400T1 (en) * 2002-11-21 2008-10-15 Epict Technologies METHOD FOR USING RIBOPRIMERS FOR STRAND DISPLACEMENT REPLICATION OF TARGET SEQUENCES
ATE525469T1 (en) 2002-12-18 2011-10-15 Third Wave Tech Inc DETECTION OF SMALL NUCLEIC ACIDS
JP2006519008A (en) 2003-02-10 2006-08-24 独立行政法人産業技術総合研究所 Regulation of mammalian cells
CA2533701A1 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
AU2004294567A1 (en) 2003-11-26 2005-06-16 University Of Massachusetts Sequence-specific inhibition of small RNA function
WO2005079397A2 (en) * 2004-02-13 2005-09-01 Rockefeller University Anti-microrna oligonucleotide molecules
US20050182005A1 (en) * 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
EP1747023B2 (en) 2004-05-04 2016-03-09 The Board of Trustees of The Leland Stanford Junior University Methods and compositions for reducing hcv viral genome amounts in a target cell
FR2873867B1 (en) 2004-07-28 2006-11-03 Valeo Electronique Sys Liaison IMPROVED DEVICE FOR CONTROLLING THE CUT AND CLOSURE OF THE CIRCUIT OF AN ELECTRIC BATTERY.
US20060089635A1 (en) 2004-10-22 2006-04-27 Scimed Life Systems, Inc. Methods and apparatus for focused bipolar tissue ablation using an insulated shaft
AU2006279906B2 (en) 2005-08-10 2012-05-10 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070213292A1 (en) * 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20090203893A1 (en) 2005-08-29 2009-08-13 Regulus Therapeutics, Llc Antisense compounds having enhanced anti-microrna activity
WO2007027775A2 (en) 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Methods for use in modulating mir-122a
CN103642900B (en) 2006-01-05 2016-04-13 俄亥俄州立大学研究基金会 For the diagnosis and treatment of the method and composition based on Microrna of solid carcinoma
EP2194129A3 (en) 2006-04-03 2012-12-26 Santaris Pharma A/S Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
DK2205737T3 (en) 2007-10-04 2013-05-21 Santaris Pharma As Micromirers
ES2610622T3 (en) 2009-03-31 2017-04-28 The General Hospital Corporation Regulation of miR-33 microRNA in the treatment of cholesterol-related disorders
DE102011086706A1 (en) 2011-11-21 2013-05-23 Robert Bosch Gmbh A method for blending a generator braking torque of a generator of a recuperative brake system with two brake circuits and control device for a recuperative brake system with two brake circuits
WO2013080784A1 (en) 2011-11-30 2013-06-06 シャープ株式会社 Memory circuit, drive method for same, nonvolatile storage device using same, and liquid crystal display device
CN103186763B (en) 2011-12-28 2017-07-21 富泰华工业（深圳）有限公司 Face identification system and method
EP2806277B1 (en) 2013-05-24 2016-03-30 3M Innovative Properties Company Closure
KR101595393B1 (en) 2014-05-22 2016-02-18 엘지전자 주식회사 Information providing system and method thereof
US10867398B2 (en) 2017-11-21 2020-12-15 Reliance Core Consulting LLC Methods, systems, apparatuses and devices for facilitating motion analysis in an environment

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598143B2 (en) 2003-11-26 2013-12-03 University Of Massachusetts Sequence-specific inhibition of small RNA function
US9334497B2 (en) 2003-11-26 2016-05-10 University Of Massachusetts Sequence-specific inhibition of small RNA function
US11359196B2 (en) 2003-11-26 2022-06-14 University Of Massachusetts Sequence-specific inhibition of small RNA function
US8658370B2 (en) 2005-08-01 2014-02-25 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
US8481505B2 (en) 2005-09-12 2013-07-09 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
US8361710B2 (en) 2006-01-05 2013-01-29 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-21
US8377637B2 (en) 2006-01-05 2013-02-19 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-17-3P
US8658362B2 (en) 2006-01-05 2014-02-25 The Ohio State University Methods for diagnosing colon cancer using MicroRNAs
US8580500B2 (en) 2006-01-05 2013-11-12 The Ohio State University Methods for diagnosing lung cancer using microRNAs
US8557520B2 (en) 2006-01-05 2013-10-15 The Ohio State University Methods for diagnosing prostate cancer using MicroRNAs
US8507202B2 (en) 2006-01-05 2013-08-13 The Ohio State University Methods for diagnosing pancreatic cancer using MicroRNAs
US9051618B2 (en) 2006-01-05 2015-06-09 The Ohio State University Methods for diagnosing lung cancer using MicroRNA signatures
US9023598B2 (en) 2006-01-05 2015-05-05 The Ohio State University Methods for diagnosing pancreatic cancer using miR-103-1, miR-103-2, miR-24-2 and miR-107
US9017940B2 (en) 2006-01-05 2015-04-28 The Ohio State University Methods for diagnosing colon cancer using MicroRNA signatures
US8603744B2 (en) 2006-01-05 2013-12-10 The Ohio State University Methods for diagnosing breast cancer using MicroRNAs
US8389210B2 (en) 2006-01-05 2013-03-05 The Ohio State University Research Foundation MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
US8512951B2 (en) 2006-01-05 2013-08-20 The Ohio State University Methods for diagnosing stomach cancer using MicroRNAs
US9017939B2 (en) 2006-01-05 2015-04-28 The Ohio State University Methods for diagnosing breast, colon, lung, pancreatic and prostate cancer using miR-21 and miR-17-5p
US8865885B2 (en) 2006-03-20 2014-10-21 The Ohio State University Research Foundation MicroRNA fingerprints during human megakaryocytopoiesis
US8486913B2 (en) 2006-03-20 2013-07-16 The Ohio State University MicroRNA fingerprints during human megakaryocytopoiesis
US8486912B2 (en) 2006-03-20 2013-07-16 The Ohio State University Research Foundation MicroRNA fingerprints during human megakaryocytopoiesis
US8492083B2 (en) 2006-03-20 2013-07-23 The Ohio State University MicroRNA fingerprints during human megakaryocytopoiesis
US8518647B2 (en) 2006-07-13 2013-08-27 The Ohio State University Research Foundation Method of diagnosing poor survival prognosis colon cancer using miR-16b
US8338102B2 (en) 2006-07-13 2012-12-25 The Ohio State University Research Foundation Method of diagnosing poor survival prognosis colon cancer using miR-181b
US8349568B2 (en) 2006-07-13 2013-01-08 The Ohio State University Research Foundation Method of diagnosing poor survival prognosis colon cancer using let-7g
US8343725B2 (en) 2006-07-13 2013-01-01 The Ohio State University Research Foundation Method of diagnosing poor survival prognosis colon cancer using miR-10a
US8338106B2 (en) 2006-07-13 2012-12-25 The Ohio State University Research Foundation Method of diagnosing poor survival prognosis colon cancer using miR-29a
US8338104B2 (en) 2006-07-13 2012-12-25 The Ohio State University Research Foundation Method of diagnosing poor survival prognosis colon cancer using miR-103-2
US8338105B2 (en) 2006-07-13 2012-12-25 The Ohio State University Research Foundation Method of diagnosing poor survival prognosis colon cancer using miR-203
US8338103B2 (en) 2006-07-13 2012-12-25 The Ohio State University Research Foundation Method of diagnosing poor survival prognosis colon cancer using miR-106a
US8431342B2 (en) 2007-01-31 2013-04-30 The Ohio State University Research Foundation MiR-182-, miR-191, miR-199a-based methods for the diagnosis and prognosis of acute myeloid leukemia (AML)
US8530159B2 (en) 2007-01-31 2013-09-10 The Ohio State University Research Foundation MiR-29-based methods for the diagnosis and prognosis of acute myeloid leukemia (AML)
US8354229B2 (en) 2007-01-31 2013-01-15 The Ohio State University Research Foundation MiR-25-based methods for the diagnosis and prognosis of acute myeloid leukemia (AML)
US8372586B2 (en) 2007-06-15 2013-02-12 The Ohio State University Research Foundation Method for diagnosing acute lymphomic leukemia (ALL) using miR-146a
US8361722B2 (en) 2007-06-15 2013-01-29 The Ohio State University Research Foundation Method for diagnosing acute lymphomic leukemia (ALL) using miR-221
US8349561B2 (en) 2007-06-15 2013-01-08 The Ohio State University Research Foundation Method for diagnosing acute lymphomic leukemia (ALL) using miR-125b
US8349560B2 (en) 2007-06-15 2013-01-08 The Ohio State University Research Method for diagnosing acute lymphomic leukemia (ALL) using miR-222
US8367632B2 (en) 2007-07-31 2013-02-05 Ohio State University Research Foundation Methods for reverting methylation by targeting methyltransferases
US9085804B2 (en) 2007-08-03 2015-07-21 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
US8466119B2 (en) 2007-08-22 2013-06-18 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of EPHA7 and ERK phosphorylation in human acute leukemias
US8911998B2 (en) 2007-10-26 2014-12-16 The Ohio State University Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof
US9125923B2 (en) 2008-06-11 2015-09-08 The Ohio State University Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
US8916533B2 (en) 2009-11-23 2014-12-23 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
US8946187B2 (en) 2010-11-12 2015-02-03 The Ohio State University Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer
US10758619B2 (en) 2010-11-15 2020-09-01 The Ohio State University Controlled release mucoadhesive systems
US11679157B2 (en) 2010-11-15 2023-06-20 The Ohio State University Controlled release mucoadhesive systems
US8664192B2 (en) 2011-03-07 2014-03-04 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
US9249468B2 (en) 2011-10-14 2016-02-02 The Ohio State University Methods and materials related to ovarian cancer
US9481885B2 (en) 2011-12-13 2016-11-01 Ohio State Innovation Foundation Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
US9434995B2 (en) 2012-01-20 2016-09-06 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis

Also Published As

Publication number Publication date
IL242135A0 (en) 2015-11-30
IL173364A (en) 2017-01-31
US8859521B2 (en) 2014-10-14
US20190062744A1 (en) 2019-02-28
US20170037403A1 (en) 2017-02-09
US9663787B2 (en) 2017-05-30
US20100249215A1 (en) 2010-09-30
US9447413B2 (en) 2016-09-20
US20100267813A1 (en) 2010-10-21
US8946179B2 (en) 2015-02-03
US20120035248A9 (en) 2012-02-09
US20060252722A1 (en) 2006-11-09
US20140121365A1 (en) 2014-05-01
US20140329882A1 (en) 2014-11-06
US8466120B2 (en) 2013-06-18
US20090286969A1 (en) 2009-11-19
EP1648914A4 (en) 2009-12-16
US20170268002A1 (en) 2017-09-21
US20170037402A1 (en) 2017-02-09
US20090298174A1 (en) 2009-12-03
US8697663B2 (en) 2014-04-15
US20150094461A1 (en) 2015-04-02
US20120122216A1 (en) 2012-05-17
US20140121364A1 (en) 2014-05-01
EP2530157A3 (en) 2015-03-18
US8110558B2 (en) 2012-02-07
US20140057963A1 (en) 2014-02-27
US20150337305A1 (en) 2015-11-26
US7683036B2 (en) 2010-03-23
WO2005013901A3 (en) 2006-03-02
EP2530157A2 (en) 2012-12-05
US8178506B2 (en) 2012-05-15
US9447412B2 (en) 2016-09-20
US9267138B2 (en) 2016-02-23
US7759319B2 (en) 2010-07-20
US8133876B2 (en) 2012-03-13
US10584336B2 (en) 2020-03-10
US20160017329A1 (en) 2016-01-21
IL173364A0 (en) 2006-06-11
US9528108B2 (en) 2016-12-27
US20180010128A1 (en) 2018-01-11
US9139832B2 (en) 2015-09-22
WO2005013901A2 (en) 2005-02-17
US8546350B2 (en) 2013-10-01
US20050261218A1 (en) 2005-11-24
US9752146B2 (en) 2017-09-05
US8809294B2 (en) 2014-08-19
IL242135B (en) 2018-10-31
US20090291907A1 (en) 2009-11-26
US10072265B2 (en) 2018-09-11
US20090291906A1 (en) 2009-11-26
US20090317907A1 (en) 2009-12-24
US20110224277A1 (en) 2011-09-15
EP1648914A2 (en) 2006-04-26
US8106025B2 (en) 2012-01-31
US20150337304A1 (en) 2015-11-26
US20140336370A1 (en) 2014-11-13
US8765701B2 (en) 2014-07-01
EP2530157B1 (en) 2016-09-28
US20120283319A1 (en) 2012-11-08
US20120157514A1 (en) 2012-06-21
US10093926B2 (en) 2018-10-09

Similar Documents

Publication Publication Date Title
CA2533701A1 (en) Oligomeric compounds and compositions for use in modulation of small non-coding rnas
Liu et al. MicroRNA profiling and head and neck cancer
Ahir et al. MicroRNAs in glioblastoma pathogenesis and therapy: A comprehensive review
Babashah et al. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis
Koturbash et al. Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis
US9416369B2 (en) Methods and compositions to modulate RNA processing
Rachagani et al. MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications
Chen et al. Noncoding RNAs: new players in cancers
Ma MicroRNA and metastasis
US20180230546A1 (en) Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers
Zhang et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real‐time PCR analysis
Sethi et al. MicroRNAs and head and neck cancer: reviewing the first decade of research
Kasashima et al. Altered expression profiles of microRNAs during TPA-induced differentiation of HL-60 cells
Huppi et al. MicroRNAs and genomic instability
Mazan-Mamczarz et al. Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL)
US9200275B2 (en) Methods and compositions for regulating cell cycle progression
US20050260648A1 (en) Method for the determination of cellular transcriptional
Zhou et al. In silico detection and characteristics of novel microRNA genes in the Equus caballus genome using an integrated ab initio and comparative genomic approach
NZ551019A (en) Method for detecting ncRNA
Zhou et al. Integrating miRNA and mRNA expression profiling uncovers miRNAs underlying fat deposition in sheep
Xia et al. MicroRNAs and their roles in osteoclast differentiation
US20170306326A1 (en) Microrna inhibitor system and methods of use thereof
Stallings et al. MicroRNA and DNA methylation alterations mediating retinoic acid induced neuroblastoma cell differentiation
Seux et al. MicroRNAs in pancreatic ductal adenocarcinoma: new diagnostic and therapeutic clues
Roy et al. An insight into the sprawling microverse of microRNAs in depression pathophysiology and treatment response

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20200831